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ABSTRACT 
Background 
Current treatment of HIV requires life-long antiretroviral therapy (ART) to suppress HIV replication. 
Adherence to medication is a critical component of treatment success, where ≥95% of doses, must be 
taken to achieve and maintain undetectable viral loads which are essential for successful patient and 
public health outcomes. Although South Africa recently introduced universal test and treat (UTT) and 
supports the largest number of people living with HIV (PLWH) on treatment in the world, there is 
limited data on long term adherence in our population.  
Objective 
The aim of this project was to retrospectively assess long term adherence in HIV infected patients on 
ART for at least five years or longer in order to inform long term care. 
Methodology 
Long-term adherence to ART was retrospectively analysed in HIV infected, ART naïve patients, first 
enrolled in a randomised controlled trial assessing tuberculosis (TB) and HIV treatment integration 
(N=642) and subsequently followed post-trial in an observational cohort study (N=402) in Durban, 
South Africa. Adherence was determined by assessing monthly or quarterly (depending on 
appointment schedule) pharmacy pill counts for patients on ART for five years or longer. 
Results 
From the initial randomized control trial cohort of 642 patients, 270 met the inclusion criteria for this 
analysis; 54.8% were female, median age was 34 years (IQR: 29-40) and median time on ART was 70 
months (IQR: 64-78). Mean ART adherence was maintained at ≥ 95% for each year on ART and 
93.9% of patients maintained viral suppression by the end of the follow up period. Pill count based 
adherence estimates showed high sensitivity (95%; 95%CI: 91-98%) in predicting viral suppression 
but poor specificity (9%; 95%CI: 0-41%) for predicting detectable viral loads at five years post-ART 
initiation. However, half of all patients had at least one sub-optimal (<95%) pill count in the first six 
months after ART initiation and <20% between the first and sixth year. Viral suppression was 87.4% 
six months after ART initiation and increased thereafter, remaining >92% throughout follow-up. HIV 
and TB co-treatment or switching to second line regimens with high pill burdens did not worsen 
adherence. Mean adherence was >99% in stable patients provided with an extended 90-day ART 
supply. 
Conclusion 
Our study found overall high adherence to ART in this South African cohort followed up over a 
period of more than five years. Treatment outcomes were successful on both first and second line 
treatment. Pill count was not a good predictor of virologic failure in our study and viral load 
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measurement should be used as the benchmark for monitoring treatment response as required by 
current guidelines. However, adherence during the initial six months after ART initiation has been 
shown to impact long term treatment outcomes, therefore, pill count may be used as a quick, simple 
measure of adherence to identify patients with early adherence challenges and provide the opportunity 
for timeous adherence interventions. Optimal long-term adherence with successful treatment 
outcomes are possible within a structured ART programme with close adherence monitoring. This 
adherence support approach and these findings are relevant in the era of UTT. 
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STRUCTURE OF DISSERTATION 
 
This dissertation was written in accordance with the Guidelines for Presentation of Masters 
Dissertations provided by the College of Health Sciences, University of Kwa-Zulu-Natal, 2015. There 
is a single reference list using Vancouver reference style for citations in chapters 1, 2 and 4. 
The dissertation comprises of the following chapters: 
Chapter 1: Introduction – this chapter presents the background on the current HIV epidemic focusing 
on the key role of adherence on HIV treatment outcomes. The literature review provides a 
comprehensive overview on methods of measuring ART adherence, factors that impact medication 
adherence and studies on long-term ART adherence. Current knowledge gaps are identified and 
provide a prelude to the problem statement and rationale for the study. The research questions raised, 
and aims and objectives through which these will be addressed, are also described here.  
Chapter 2: Methods – this chapter details the study setting, selection of the study population from the 
SAPiT and TRuTH parent studies, data collection, validation and clean up procedures and 
methodology for secondary analysis 
Chapter 3 - Manuscript titled ‘Long Term Adherence to Antiretroviral Therapy in a South African 
Adult Patient cohort’ submitted for publication to the journal AIDS Patient Care and STDs. It is 
presented in the required format of the journal and is the final submitted version approved by all co-
authors. The objectives and aims of the study were addressed in this manuscript.  
Chapter 4: Discussion – this chapter is an overall discussion of the study findings and places them in 
context with findings from other long-term adherence studies. Recommendations for clinical practice, 
the role of the pharmacist in monitoring and supporting adherence in patients on lifelong ART and 
possibilities for future research are also discussed.
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CHAPTER ONE: INTRODUCTION 
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CHAPTER 1: INTRODUCTION 
1.1 Background and the context for the study 
More than three decades have passed since the human immune deficiency virus (HIV) was discovered 
in 1983 (1). Since the start of the epidemic, HIV has infected 70 million people and claimed the lives 
of approximately 35 million people globally (2). Currently, an estimated 36.9 million people are 
living with HIV (PLWH) worldwide (3). Sub-Saharan Africa (SSA), where an estimated 3200 new 
infections occur daily, bears the highest HIV infection burden globally (2, 3). In this region, South 
Africa is the country with the highest adult HIV prevalence (18%) and has approximately 7.5 million 
PLWH, the largest globally (4, 5). 
There is currently no known cure for HIV infection (6, 7). Treatment involves the use of combination 
antiretroviral (ARV) drugs which suppress replication of HIV thereby slowing down disease 
progression and destruction of CD4 cells that are vital to immune system function (8). Zidovudine 
was the first ARV drug to be licensed by the United States Food and Drug Administration (FDA) in 
1987 and 28 years later we now have six different classes of ARVs comprising more than twenty five 
individual ARV drugs (9). The advent of antiretroviral therapy (ART) has changed the face of the 
HIV epidemic by dramatically reducing morbidity and mortality in PLWH. With early initiation of 
ART, life expectancies for PLWH are now approaching that of the general population (10-12). To 
lower morbidity and prevent premature mortality ART must be used life-long in order to maintain 
viral suppression and consequentially HIV is managed as a chronic disease. 
In South Africa, the government funded national ARV programme is the largest of its kind in the 
world providing ARV treatment and care to over four million people (13). In May 2016 the Minister 
of Health announced that CD4 thresholds would no longer be used as a criterion for ART eligibility 
and a universal test and treat (UTT) policy was implemented on 01 September of that year (14). This 
test and treat policy followed updated WHO guidelines from September 2015, based on new 
evidence, that demonstrated starting ART as soon as possible after HIV diagnosis improves morbidity 
and mortality outcomes (15, 16). With the implementation of this policy, the number of HIV infected 
individuals eligible to start antiretroviral treatment is set to escalate substantially. However, increased 
access to ART is only one aspect of an effective HIV management programme. As treatment 
programmes scale up our public health facilities face the challenge of rapidly providing pre-ART 
initiation education and adherence counselling after an HIV infection diagnosis, thereafter, continuing 
to monitor and provide adherence support and counselling in addition to retaining patients in life time 
care, all within limited budgets and insufficient human resources (17). 
Medication adherence in the context of HIV infection remains critical, as near perfect adherence 
levels (≥95%) are required to achieve and maintain viral suppression (18). This adherence value was 
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based on an early study in patients receiving unboosted protease inhibitor (PI) regimens although 
subsequent studies have reported that viral suppression can be attained at lower adherence levels with 
non-nucleoside reverse transcriptase inhibitor (NNRTI) and boosted PI regimens (19-21). However, 
sub-optimal adherence can lead to inadequate concentrations of ARV drugs allowing continued HIV 
replication and development of drug resistance (22). Indeed, cumulative adherence levels of <100% 
and treatment interruptions have been found to be associated with an increased risk of treatment 
failure and resistance to nucleoside reverse transcriptase inhibitor (NRTI) and NNRTIs (23-28). This 
can have several negative consequences on both individual and public HIV healthcare. Firstly, poorly 
adherent patients who acquire resistance to first line NNRTI-based regimens are switched to second 
and third line ARV regimens which are costlier, have a higher pill burden, increased dosing frequency 
and often have less tolerable side effects (29, 30). Access to second line, third line and salvage 
treatment regimens are also limited or may be unavailable in resource constrained healthcare settings 
(31-33). Secondly, resistant HIV strains can be transmitted to others resulting in primary resistance to 
first line treatment regimens in newly infected ARV-naïve patients or acquired resistance in infected 
patients already on ART (34). Thirdly, treatment failure due to non-adherence is associated with a 
greater risk of progression to Acquired Immune Deficiency Syndrome (AIDS) and mortality (35, 36). 
Hospital admissions due to HIV disease progression and opportunistic infections in poorly adherent 
patients further add to the burden of public healthcare costs (37-39). Therefore,  although NNRTI and 
boosted PI regimens may be more robust despite imperfect adherence, it is still advocated that high 
adherence levels be maintained to achieve optimal viral suppression, good treatment outcomes and 
ensure durability of current available treatment regimens (34, 40). 
Adherence to chronic medication is generally not a static phenomenon and patients may alternate 
between periods of optimal and poor adherence (41-43). Medication adherence rates in chronic non-
communicable diseases have been shown to be as low as 50% with discontinuation of therapy usually 
occurring within six months following treatment initiation (37, 44). Poor adherence levels have also 
been found in infectious diseases requiring long term therapy such as hepatitis C and tuberculosis 
(TB) (45, 46).  
Studies on short term adherence to ART (from initiation up to two years on treatment) in South 
African patients have reported adherence rates ranging from 63 to 88% (47-51). However, ART is a 
chronic, life-long treatment and there is a lack of information on long term adherence in this 
population. There is a strong emphasis on adherence support and interventions in patients initiating 
ART but without knowledge on levels of adherence and the facilitators and barriers to adherence over 
the long term, assisting patients to achieve optimal adherence will remain a challenge. This research 
aims to address these knowledge gaps by providing insight into long term adherence rates, the factors 
that influence long term adherence (at least five years or longer) to ART and suggests ways to best 
monitor adherence in a resource constrained setting.  
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1.2 Literature Review 
Adherence may be broadly defined as “the extent to which a person’s behaviour – taking medication, 
following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a 
health care provider” (44). Patients on ART must take the prescribed number of pills, and doses per 
day, in addition to following any required dietary and/or fluid restrictions. Studies on ART adherence 
report optimal adherence to be within the range of ≥ 80-100% of the prescribed doses taken in a 
specified time period (52, 53). Medication adherence assessed across a spectrum of chronic diseases 
including hypertension, hypercholesterolaemia and Type II diabetes have been found to be suboptimal 
with adherence levels reported to be ranging from 37 to 72% (54). Thus, achieving near perfect 
adherence levels required for successful chronic ART can pose a significant challenge to patients and 
HIV care providers. 
1.2.1 Measures of Adherence  
Medication adherence may be measured using indirect and direct methods. Indirect adherence 
measures include patient self-report, pill counts, prescription refills and electronic monitoring (37, 55, 
56). With indirect methods, adherence is generally reported as a rate; usually a percentage of the 
number of doses taken by the patient over a specified time-period. Direct methods include direct 
observation of treatment taken, monitoring of drug levels or measuring biomarkers (56). These 
methods provide objective adherence data however due to higher costs and skilled labour 
requirements they are rarely used in non-research settings in drugs without a narrow therapeutic range 
(37). Direct adherence measures are usually report adherence as a dichotomous variable, either 
adherent or non-adherent, depending on the detection of drug concentrations in plasma, peripheral 
compartments, or by other biomarkers (57). 
Indirect adherence measures 
Self-report of medication use is a widely utilised, simple, cost-effective adherence measure where the 
patient is asked to recall the number of doses taken or missed over a specific period of time before 
their clinic visit (58). Periods of recall vary widely between studies and range from a few days up to a 
three months prior to the visit (59). Adherence may be assessed in the form of an unstructured 
interview, structured questionnaire, such as the commonly used Adult AIDS Clinical Trial Group 
(AACTG) instrument and Morisky Medication Adherence Scale (MMAS), or a Visual Analogue 
Scale (VAS) (60-62). The VAS is a linear scale that uses numbers (0-10) or percentages (0-100%) and 
the patient then selects a point on the line that they think corresponds to their adherence level over the 
recall period. Self-report is quick and easy to administer but results are prone to bias. Patients may 
misrepresent their adherence for various reasons; fear of criticism, desire to portray good adherence to 
care providers, to avoid being probed on reasons for missed doses or be truthfully unable to recall 
missed doses, leading to an overestimation of adherence. (63, 64). Self-reported non-adherence, on 
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the other hand, has been shown to be a more reliable indicator of viral suppression and clinical 
outcomes (64, 65).  
Adherence values may also change depending on the type of self-report method used and the recall 
time period over which adherence is assessed (66, 67). For example, Gao et al. (66) compared self-
report adherence values obtained from a Morisky-type questionnaire, a 2-day recall period and a 2- 
week recall period. Only 29 % of patients were classified as highly adherent using the Morisky scale 
whereas 93% and 96% were highly adherent using the 2-day and 2-week self-report. Although various 
self-report adherence assessment tools have been developed, there is a lack of consensus on the 
selection of a validated, reliable and standardized self-report measure (58, 59). Strategies to improve 
the reliability of self-report include; using a validated self-report adherence tool for the sample 
population, reducing possible report bias by using written or computer assisted surveys rather than 
face-to-face questionnaires, selecting self-report measures that target the adherence behaviour under 
investigation and having different clinic staff conduct adherence assessments from those who provide 
adherence counselling and support to minimize social desirability bias (68).   
Pill counts, and pharmacy prescription refills are quick and inexpensive methods for measuring 
adherence making them suitable for use in resource limited settings. Pill count adherence is generally 
calculated as a percentage using the formula below (69): 
          (number of doses dispensed - number of doses remaining) aaaaaaaa    x 100   x100                                
(prescribed number of doses per day × number of days between the visits)  
  
Prescription refill data is also used to monitor adherence by utilizing available information from 
pharmacy dispensing records. However, treatment has to be collected from a single pharmacy or a 
pharmacy within a linked network in order to be able to monitor adherence (37). Adherence from 
pharmacy refill records is determined by calculating the Medication Possession Ratio (MPR) or Drug 
Possession Ratio (DPR) from the following formulae (70-72). 
MPR = total number of days supplied with drug in a time period 
             number of days from first to last refill in the time period  
 
DPR= days’ supply of drugs delivered - the days’ supply of drugs returned 
                                  number of days between clinic visits   
                     
Although not affected by reporting bias these methods may be subject to inaccurate estimations of 
adherence. Pill counts and prescription refills do not provide information on dose timing and there is 
no way of determining if the medication is being taken as prescribed. Pill counts can’t be accurately 
calculated if tablets are lost or not brought back by the patient. Pill dumping, where patients return the 
expected number of tablets and discard the remainder, also presents a false picture of true adherence 
(37, 73). These obstacles can be avoided by conducting unannounced pill counts, where an 
unscheduled pill count is done outside the health facility (at the patient’s home). Adherence assessed 
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using unannounced pill counts has been shown to correspond with viral load counts, however, they 
are costly and time consuming to conduct and are therefore not feasible for routine use in public 
health care settings (74). Other studies have reported adherence measured using unannounced pill 
counts, VAS and electronic monitoring were comparable and similarly correlated to viral load 
suppression (75, 76). Prescription refill data can underestimate adherence if the patient has extra doses 
that were taken and can overestimate adherence if the patient collects a refill early. Despite their 
limitations these pharmacy adherence measures have been shown to be superior to self-reported 
adherence and can assist in predicting virologic outcomes in HIV patients on ART (77-79). 
Electronic monitors are a more recent technology gaining popularity in trial settings however they are 
costly devices for treatment scale up. The most common type is a Memory Event Monitoring System 
(MEMS) cap which is fitted onto the medication bottle. A data chip in the device records the date and 
time the medication bottle is opened to remove a dose (80). Objective data can be obtained on dose 
frequency and time, and data can be captured over extended periods of time. However, opening the 
cap or removing the dose of medication from the bottle is not a guarantee that it was taken and 
patients may also remove more than one dose from the bottle at a time which can lead to inaccurate 
adherence data (37). A review of studies comparing MEMS to other adherence measures found that 
electronic monitoring systems provided a more accurate adherence assessment than self-report and 
pill count, which overestimated adherence by 17% and 8% respectively (80). However, a review of 
studies comparing MEMS and self-reported adherence only found two-thirds of studies demonstrated 
moderate (27.9%), high (11.6%) or significant (23.3%) correlation between these the two adherence 
measures (81). 
Routine viral load testing (at six months after ART initiation and thereafter annually) is the 
recommended standard for monitoring patient response to ART, with an undetectable plasma viral 
load (<50 copies/mL), used as a proxy for adherence to treatment (82, 83). Although viral load 
measurement is the current benchmark for ART monitoring it is not without limitations. Studies have 
shown that patients can still have an undetectable viral load despite imperfect adherence, and these 
patients are at risk of ongoing low level viral replication in non-plasma compartments (84, 85). 
Virologically suppressed patients with suboptimal adherence were found to have a 50% increased risk 
of subsequent viral load rebound (86). Annual testing can allow for patient non-adherence to go 
undetected for up to a year until the next viral load measurement becomes detectable, thereby 
increasing the risk of treatment failure. It is also not possible to differentiate whether a detectable viral 
load is due to non-adherence or other causes such as drug resistance or suboptimal drug levels 
(secondary to drug interactions, malabsorption or other patient factors). Furthermore, due to the 
infrastructure and skilled labour costs involved, routine viral load monitoring may either be 
unavailable or have limited accessibility in low income countries (87, 88). There are also operational 
drawbacks; viral load results are not immediately available, clinics may lack or have inadequate 
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systems in place to receive and follow up on viral load results; patients with a detectable viral load 
result may be uncontactable; and patients successfully contacted then have to make a return visit to 
the clinic for further follow up (89). Point of care viral load testing may circumvent many of these 
operational challenges as it can be more cost-effective for scale up and provide same day results but 
there is insufficient evidence available at this stage to recommend wide scale use in public health care 
settings (90, 91).  
Direct adherence measures 
Measurement of ARV plasma or urine drug concentrations are not routinely used for adherence 
monitoring. Apart from the high cost and non-availability in many resource limited settings, 
therapeutic drug monitoring (TDM) has not been found to provide additional benefit over other 
routine adherence measures such as self-report and pill count (57, 67). Patients undergoing drug level 
monitoring may also only adhere to medications immediately prior to clinic visits (92). Using TDM to 
monitor ARV drug levels can be useful in patients at risk of drug-drug interactions between ARVs 
and other concomitant medication and those susceptible to altered drug metabolism due to age, 
physiological abnormalities or co-morbid conditions (93, 94). Dried blood spots (DBS) is a newer 
method being used to measure ARV blood concentrations and are simpler to collect than traditional 
venous phlebotomy blood samples (95). A few blood drops from a finger prick are collected on a 
special filter paper and allowed to dry. The DBS is then placed in a sealed plastic bag with a desiccant 
and sent to a laboratory for analysis (96). The DBS method does not provide a continuous measure of 
adherence over time but instead whether detectable concentrations of the ARV drug are present above 
a certain threshold at the time the DPS sample is taken (97). Viral load monitoring and resistance 
testing are also possible with DBS making it possible to compare ARV concentrations with virologic 
outcomes (96). A study in HIV infected pregnant women on ART found DBS to be more accurate 
than self-report at assessing adherence, with 89% of women reporting perfect adherence by self-report 
versus 74% adherence determined by ARV concentration in DBS (97). In a West African study, 
therapeutic concentrations of efavirenz (EFV) and nevirapine (NVP) from DBS where found to 
correlate with viral load suppression (98).  
Measuring the concentration of ARV drug in hair is another novel bio-sampling method being used to 
determine cumulative adherence to ART (99). A small sample of hair, around 10 to 20 strands, 
proximal to the scalp is cut from the occipital section of the head (100). Antiretroviral drug levels in 
the hair are determined using liquid chromatography/tandem mass spectrometry (LCMS) (101).  
Unlike traditional TDM that measure drug concentrations at a point in time, drugs levels detected in 
hair samples can be indicative of adherence over a period of weeks to months thereby providing a 
longitudinal picture of adherence (102). Baxi et al. (103) demonstrated hair concentrations of NVP 
were predictive of viral load suppression and patients with hair concentrations in the highest quintile 
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were nine times more likely to have viral suppression compared to patients with concentrations in the 
lowest quintile. Similarly, atazanavir (ATV) hair concentrations have also been shown to predict viral 
load outcomes with increasing drug concentrations in hair corresponding to better odds of an 
undetectable viral load (100). In a study conducted in pregnant women, EFV and Lopinavir (LPV) 
hair concentrations measured pre- and post-partum were the strongest predictor of viral load 
suppression at the time of delivery (104). Compared to traditional TDM methods, hair sampling is 
non-invasive, does not require skilled staff for sample collection and is less expensive. In settings with 
poor access to viral load monitoring, ARV hair levels could be an alternative method for monitoring 
adherence.  
Ingestible biosensor systems are the latest advance in the field of adherence monitoring (105). The 
system consists of an oral ‘digital pill’, a signal receiver and a cloud or web-based server. The drug is 
embedded with a biosensor during manufacture or co-encapsulated within a gelatine capsule 
containing the biosensor at the time of dispensing. The embedded or encapsulated drug is ingested 
and after dissolution in the stomach the biosensor emits a unique signal on contact with gastric fluids, 
between 30 minutes to 2 hours post-ingestion. The signal is transmitted to a small external receiver 
worn by the patient. Receivers can be enclosed within a skin patch, mounted on a hip belt or worn 
around the neck. The data from the receiver, which provides information on the drug name, dosage, 
date and time of medication ingestion, is then transmitted to a cloud or web-based server. The 
information can be retrieved on a computer or mobile device using a smartphone application or short 
message system (SMS) and is accessible to both the patient and health care provider. The undigestible 
sensor is excreted in the faeces after passage through the gastrointestinal tract (105, 106). The use of 
ingestible biosensors for ART adherence monitoring is being investigated (107). There are several 
drawbacks to the system; the sensor or receiver can fail and no data is transmitted even though the 
medication dose has been taken, patients may find the extent of continuous monitoring intrusive and 
technology requirements and costs may not make its use unfeasible in real world resource limited 
settings. The first FDA approved digital medicine system, Abilify MyCite, an antipsychotic drug used 
for the treatment of schizophrenia and bipolar disorder, was launched in November 2017 (108). 
Importantly, the manufacturers concede that the system is not indicated to improve adherence (109). 
This highlights the need for further research in determining the role of ingestible digital tracking 
systems in modifying adherence behaviour. 
There is a great degree of heterogeneity amongst adherence studies with respect to patient 
populations, study design, methods used to measure adherence, time period per adherence assessment, 
choice of optimal adherence level and duration of follow up. Hence, while general trends may be 
observed it is difficult to generalize results between studies using different or even the same measure 
of adherence. Despite the tendency to overestimate adherence, self-report is the most commonly used 
adherence measure as it can be easily adapted for almost any type of patient setting. In resource 
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limited settings the combination of self-report with other low cost adherence measures such a pill 
count or prescription refill can provide a more accurate adherence assessment (110). Pill count and 
refill data have also been found to be superior to self-report in predicting viral outcomes and treatment 
failure (57). Although MEMS has the advantage of providing accurate data on daily dosing and dose 
timing, its high cost makes it unsuitable for use in real world patient settings (69). Developing 
technologies such as DBS and hair sampling have demonstrated favourable results in predicting 
adherence when compared to viral load but their application is currently limited to the research setting 
(99). The aim of ART is to suppress viral replication to undetectable levels in the blood, therefore 
viral load monitoring is considered the gold standard for monitoring adherence and response to 
treatment (89). However, viral load measurements do not provide information on adherence behaviour 
such as missed doses, missed pharmacy refills or reasons for non-adherence. Using viral load in 
combination with other adherence measures can improve the accuracy of adherence assessments, 
enable earlier detection of adherence problems and allow for timeous adherence support before 
viremia occurs (78, 111).  
1.2.2 Factors Influencing Adherence to ART 
Adherence to ART may be influenced by five aspects; patient factors, treatment regimens, disease 
factors, socio-economic factors and the health care system (44). These are discussed in further detail 
below. 
 Patient factors 
Patient-related variables that may impact on adherence include demographics, culture and belief 
systems, acceptance of HIV status, psychosocial factors and self-efficacy (confidence in being able to 
take medication correctly) (112, 113). Although some studies have reported associations between 
adherence and demographic variables such as age, gender and race others have found no significant 
relationship between them (113).  
Forgetfulness is a common reason for missing ART doses and is one the most frequent patient 
reported reasons for non-adherence in SSA patients (114, 115). “Simply forgot’’ was given as the 
reason for missed doses in over 40% of patients in a study by Bhat et al. (116) in rural South Africa. 
In studies conducted in Nigeria and Kenya, a third of patients reported forgetting doses in the 
previous week and month respectively (117, 118). Other frequent patient reported reasons for non-
adherence include being busy, being away from home and changes in daily routines (119). 
In ART adherence studies that report an age-adherence link, older age is usually associated with 
higher adherence levels. A meta-analysis by Ghidei et al. (120) found a 35% decrease in the risk of 
non-adherence amongst those aged 45-55 years old. A large United Kingdom cohort study found 
improved odds of achieving ≥ 95% adherence for every 10-year increase in age (121). Younger age 
(<30 years) has been associated with poorer adherence in several studies (42, 122-124). In older 
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patients (≥50 years) on the other hand, adherence may be impaired due to age-associated cognitive 
impairment but this has not been a consistent finding (125-127). Elderly patients may also have a 
higher medication burden and experience medication-related adverse effects due to treatment for co-
morbid conditions including cardiovascular disease, diabetes and cancer, which can present a barrier 
to maintaining optimal adherence to ART (128). 
Studies in developed countries have reported a lower proportion of women achieve optimal adherence 
to ART when compared to men (129). Gender differences with respect to ART adherence must be 
interpreted within the broader context of other psychosocial factors, such as injection drug use (IDU),  
alcohol use and depression, which are more prevalent amongst women with poor adherence in 
developed countries (43, 129-131). However, a Canadian study found female gender to be 
independently associated with poorer long term adherence to ART with 57% of women optimally 
adherent to ART compared to 77% of men (132). Gender differences in adherence to ART have not 
been consistently shown in resource limited countries. In a Senegalese cohort, women were 37% more 
likely to achieve optimal adherence to ART than men (133). However, Boulle et al. (134) reported no 
association between gender and self-reported adherence in a Cameroon cohort, although men were 
found to be at greater risk for virological failure. Nevertheless, HIV infected women in developing 
countries tend to demonstrate better health seeking behaviours than men which may be motivated by 
their role as the primary care giver in their families (135, 136). Woman access healthcare more 
frequently through the use of family planning and antenatal clinic services and are thus more likely to 
access HIV testing and initiate ART than men (137, 138).  
Immigrants and minority ethnic groups in developed countries are less likely to achieve optimal ART 
adherence although socio-economic challenges such as unemployment, immigrant status, insecure 
housing and cultural and language barriers may be contributing factors toward the poorer adherence 
observed (139-141).  
Alcohol abuse and active substance abuse are well established barriers to ART adherence. Alcohol 
abuse reduces adherence by as much as 50-60% with increasing amounts of alcohol consumption 
corresponding to declining adherence levels (142). Illicit drug users have a four times greater risk of 
poor adherence compared to non-drug users (143). Non-adherence may be to unintentional due to 
intoxicating effects or intentional due to uninformed concerns about interactions between ARV 
treatment and alcohol or illicit drugs (142, 144). Although much of the current evidence is based on 
studies in resource rich settings similar trends, particularly with relation to alcohol, are evident in 
African countries (145, 146). In recent years, the use of a drug cocktail containing ARV drugs 
amongst substance abusers has emerged in South Africa. Known colloquially as “Whoonga”, it 
reportedly contains a mix of illicit drugs with crushed ARV drugs, usually EFV, added in and the 
concoction is then smoked (147). The presence of ARV drugs in Whoonga does not provide any 
11 
 
therapeutic effect and it is smoked solely to induce an intoxicating effect. Recreational use of ARV 
medication may impact on adherence through the diversion of medication for Whoonga use through 
theft of ARVs from HIV patients (147, 148). 
Psychological issues such as stress and depression has been found to be a barrier to ART adherence as 
feelings of hopelessness, difficulty in coping with HIV related issues such as stigma, and the need for 
life long treatment, can impair motivation to adhere to ART (149-151). A meta-analysis of ART 
adherence studies in SSA populations found levels of optimal adherence to be 55% lower in depressed 
patients compared to those without depression (152). Another meta-analysis that compared findings 
across low and middle income countries reported an overall 42% reduction in the probability of 
achieving ≥80% adherence levels in depressed patients with no differences in the rates of depression 
reported between the different income countries (153). However, a significantly higher proportion of 
depressed patients from low income countries compared to high income countries achieved ≥80% 
adherence (153). 
Fear of stigmatisation can lead to non-adherence as patients may hide medication and miss doses to 
avoid disclosing their status to a partner or family members. For women; fear of partner violence, 
accusations of infidelity and withholding of financial support are barriers to disclosing HIV status to 
their partners (154-156). Strong interpersonal relationships that provide social support and allow safe 
disclosure of HIV status has been reported to aid adherence (115). 
Traditional, complementary and alternative medicines (TCAM) are often used as adjunctive therapy 
to ART amongst HIV positive patients across high- and low-income regions (157). Reasons for 
TCAM use include management of ARV side effects, to improve immune function and treat HIV 
related co-morbid conditions (158, 159). Patients may decide to use complementary and alternative 
medicines (CAM), such as immune boosters, vitamin or dietary supplements, and stop their ART 
leading to non-adherence to their treatment. Studies in developed countries have found CAM use did 
not affect adherence to ART (158, 160). In African countries, studies have shown mixed results with 
some finding CAM use had no effect on ART adherence and others reporting poorer adherence due to 
CAM use (159, 161, 162). Despite their widespread use, patients often do not disclose CAM usage to 
healthcare providers and non-adherence to ART due to concomitant CAM use is unlikely to be 
discovered (160, 163). Therefore, it is important for health care practitioners to openly discuss TCAM 
use with patients in order avoid potential adverse effects, drug interactions and poor adherence 
secondary to TCAM use. 
 Socio-economic factors 
A review of earlier studies up to 2005 by Falagas et al. (164) reported that socio-economic factors 
such as income, employment status and education were not a determinant of ART adherence, 
however, the majority of the studies reviewed at the time were conducted in the USA. A review on the 
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effect of socio-economic conditions on adherence in middle and low-income countries did not find a 
definitive association between socio-economic factors and adherence, however, financial difficulties, 
poverty, lower level of education and unemployment were found to impair adherence (165). For 
women taking care of children, it has been reported that those caring for two or more children are less 
likely to maintain optimal adherence to ART and each additional child in the household results in 
women having a 6% lowers odds of achieving optimal adherence (166).  
In a resource limited region such as Africa, where high levels of poverty and unemployment prevail in 
most countries, low socioeconomic status may have a greater influence on adherence. Unstable 
housing, lack of food security, migrant work, inability to afford transportation costs to attend clinic 
visits, payment of clinic fees and low education levels are significant structural barriers to optimal 
ART adherence (115, 135, 167-169). As a result, patients may struggle to remain in care and continue 
on ART treatment and are frequently lost to follow up (170). 
 Treatment factors 
Complex ARV regimens, high pill burden, dosing more than once a day, food restrictions and special 
drug storage requirements can impair adherence to ART (171-173). The use of fixed-dose ARV 
combination tablets, enteric coated formulations, selection of drugs that do not require special storage 
(for example LPV/r tablets that do not require refrigeration) and simplifying ARV regimens to fit in 
with the patient’s routine have been shown to assist in overcoming these adherence barriers (174-
177).  
Antiretroviral side-effects and toxicity present another challenge to adherence. Transient (nausea, 
diarrhoea, fatigue, drowsiness) or persistent (neuropsychiatric symptoms, peripheral neuropathy, 
dyslipidaemia, lipodystrophy) ARV related side effects can cause patients to interrupt or discontinue 
ART (178-180).  
With the phasing out of older ARVs, such as stavudine (D4T), didanosine (ddI) and unboosted PIs, 
the introduction of newer, more tolerable ARVs and various fixed-dose ARV combinations, treatment 
regimen factors such as high pill burden, side effects or toxicity has become less of a barrier to 
adherence over the years (181).  
 Disease factors 
Disease severity may affect adherence behaviour with asymptomatic HIV infected patients exhibiting 
lower adherence to treatment than those who are ill or have a history of opportunistic infections (182). 
This may be of particular relevance to UTT, where asymptomatic patients that feel well are initiated 
on treatment and may be less motivated to adhere to treatment. The desire to be well again or remain 
healthy after being ill may influence symptomatic or previously symptomatic patients to maintain 
good adherence (182).  
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Human immunodeficiency virus associated neurocognitive disorders has been shown to reduce ART 
adherence although further research in this area is needed to determine the exact relationship between 
ART adherence and cognitive impairment (183, 184).  
Increased pill burden due to additional treatment prescribed for opportunistic infections, chronic or 
acute conditions may also have a negative impact on adherence (185). Tuberculosis is the most 
common HIV-associated opportunistic infection with half of all new infections occurring in PLWH, 
87% of whom are on ART (186). Apart from the increased pill burden, ARVs and anti-TB drugs 
cause similar side-effects, including rash, gastrointestinal side effects and peripheral neuropathy, 
which may impair patient adherence to ART (187, 188). Finally, as with other chronic conditions, the 
need to remain on life-long therapy may lead to treatment fatigue resulting in non-adherence and 
intentional treatment interruptions (189, 190). 
 Health care system 
The relationship between patient and health care providers may serve as a facilitator or barrier to 
adherence. Provision of inadequate HIV and ART education, poor counselling skills, lack of 
adherence support and uncaring health worker attitudes can lead to incorrect use of medication and 
non-adherence (124). Language barriers can be a problem in developing countries where health care 
workers are unable to converse in the local language. Patients may not be able to communicate 
treatment concerns and adherence challenges or understand verbal and written instructions that are not 
in their first language (135). 
Lack of easy access to health care facilities, particularly in rural areas, high patient clinic loads and 
lengthy waiting times at clinics may indirectly affect adherence to treatment (191). Transportation 
costs and having to take time off work due to long waiting times at clinics make it difficult for 
patients to receive regular treatment (169). Charging user fees may cause patients to miss 
appointments or scheduled drug refills if they have no money (135).  
Although shortages and stock outs of medications is a global issue, it is a frequent experience for 
many patients in developing countries (192-195). Stock outs impact adherence directly as patients are 
forced to leave the healthcare facility with no medication, an inadequate supply of medication or their 
treatment regimen must be altered, possibly to a less effective or less tolerable regimen (193, 196, 
197). Patients may be unable to afford the cost of repeated clinic visits if a short supply is dispensed 
and may run out of treatment as a result. In South Africa stock outs are often due to a breakdown in 
the drug supply chain. A recent survey found that 16 % of facilities in South Africa reported at least 
one stock out of an ARV or TB medicine over a three month period (198).  
14 
 
1.2.3 Adherence to ART 
Antiretroviral therapy became available to patients in developed regions around the mid-eighties and 
to African patients only in the early 2000’s. Access to ART in African countries was made possible 
by reductions in the cost of drugs and the concerted efforts of donor organisations such as Global 
Fund and the President's Emergency Plan for AIDS Relief (PEPFAR) (199, 200). In South Africa, 
efforts to provide treatment to PLWH were delayed, with detrimental consequences, due to AIDS 
denialism by the government at the time (201). Finally, in late 2003 after intense lobbying by 
activists, the South African government began a roll out of its first national program providing free 
access to ART (202).  
Concerns were initially expressed about the ability of patients in developing countries to achieve and 
maintain the high adherence levels required for ART. Poverty, low levels of education and literacy, 
lack of health care worker skills and poor infrastructure were amongst the issues raised as barriers to 
successful treatment outcomes and fears of widespread drug resistance were raised (203-205). 
However, early studies in Africa found patients were able to achieve optimal adherence levels and 
outcomes were comparable to those in developing countries (50, 75, 206). 
Adherence to ART in developed and developing countries 
A meta-analysis on ART adherence studies conducted up to April 2006 in North America and Africa 
reported 55% of North American patients and 77% of African patients attained optimal adherence 
(52). The authors noted that North American patients had a longer duration of ARV exposure and 
treatment regimens were more complex which may account for the lower adherence rates observed. In 
contrast, studies in Africa reflect adherence seen in ART naïve patients recently initiated on ART 
using standardized regimens (52). While initial high adherence rates in African patients are 
encouraging, as treatment programmes expand, retaining patients in care and maintaining good 
adherence levels over the long term may be a challenge (207, 208).  
A 2016 review of adherence studies in Latin American and Caribbean patients on ART reported a 
pooled adherence rate of 70%, similar to adherence levels reported from developed countries (209). 
Within these regions, adherence rates were better (80%) in the low and low-middle income countries 
compared to middle income countries (70%) (209). Alcohol abuse, unemployment, depression and 
substance abuse were reported adherence barriers (209).  
Mhaskar et al. (210) conducted the first meta-analysis assessing ART adherence in India and also 
reported a pooled adherence of 70%, although the quality of evidence from studies was noted to be 
poor.  
Ortego et al. (53) conducted a 2011 meta-analysis on adherence studies from Africa, the Americas, 
Western Europe and Asia and found only 62% of patients reported adherence levels ≥ 90%. A greater 
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proportion of patients in developing countries and men who have sex with men (MSM) were found to 
report ≥ 90% adherence (53).  
A cohort study comparing optimal ART adherence (≥ 95%) between patients in Asia and SSA, two 
regions with high HIV incidence, found Asian patients reported optimal adherence at 95% of visits 
and SSA patients at 93% of visits (196). Adherence also improved over time with the number of 
patients reporting <95% adherence reduced by half in the African cohort and by 70% in the Asian 
cohort over a two year period (196). Within each region, patients from high income countries had 
better optimal adherence rates than those who lived in middle and low-income countries (196). 
Determinants of suboptimal adherence in SSA patients included male gender, younger age, 
concomitant medication and receiving treatment at a public facility and in Asian patients MSM had 
0.6 lower odds of sub-optimal adherence compared to heterosexual patients.  
Long term ART adherence 
A PubMed search was conducted up to the end of June 2018 using the MeSH terms ‘antiretroviral 
therapy, highly active’ and ‘adherence, medication’. The search was refined to identify long term 
adherence publications by adding the search terms ‘long term’ and ‘longitudinal’ and excluding 
‘cross-sectional’. Results were restricted to publications in English and studies conducted in ages 19+ 
years. Studies were included if the reported follow up time (mean or median) was at least 2 years and 
longer (Table 1). 
In the reviewed literature, long term adherence studies conducted in developed countries include a 
larger proportion of males and key risk populations (e.g. MSM and IDUs) whereas in developing 
countries, where women bear a disproportionate burden of the HIV epidemic, studies include a higher 
percentage of women.  
In developed countries, long-term adherence to drug therapy for chronic disease conditions has been 
found to be suboptimal and similar findings have been observed with adherence to ART (44, 54). 
Knobel et al. (28) investigated long term adherence in a Spanish cohort over a median follow up 
period of 8.3 years and only 62% of patients had ≥90% adherence at their last year of follow up. 
Interestingly, in patients on treatment for more than 3 years, a third of those who had been adherent 
became non-adherent whereas just over 40% of patients initially non-adherent became adherent whilst 
only one third of patients were able to maintain continuous optimal adherence thus demonstrating the 
dynamic nature of adherence behaviour (28). A similar trend in declining adherence was reported in a 
Canadian cohort study where adherence measured by pharmacy refill dropped from 79% at 6 months 
to 72% at 24-30 months post ART initiation (35). In an Italian cohort, where adherence was assessed 
using self-report and pharmacy refill, there was a drop in the proportion of patients with ≥90% 
adherence from 88% six months after ART initiation to just below 80% after 12 months, although the 
incidence of sub-optimal adherence halved after 24 months which could suggest a possible reduction 
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in non-adherence rates in patients who have been on long term ART (211). A study incorporating self-
reported adherence data from separate MSM and female cohorts over a five year period reported 
declining adherence amongst white MSM (91% to 80%) whereas adherence rates were stable but 
lower in black MSM and women at 75% and 77% respectively (43). In women, substance abuse and 
alcohol use were associated with poor adherence and in men depression and substance abuse 
predicted lower adherence (43). Puskas et al. (132) investigated the effect of gender on long term 
adherence and demonstrated significantly lower proportion of women were ≥95% adherent to ART 
compared to men (57% vs 77%). A study conducted on the large French Anti PROtease Cohort 
(APROCO) cohort, consisting of over a thousand patients on ART, reported only a quarter of patients 
maintained optimal adherence based on self-report over a ten year follow up period (212). Being 
European born, depression, IDU, ARV side effects, PI regimen, once daily and three or more times a 
day dosage regimens were associated with moderate to low adherence (123).  
Several other studies conducted in developed countries have shown an improvement in ART 
adherence over time. In a United Kingdom study in patients on ART for up to 13 years, the odds of 
attaining >90% adherence increased 2% for each year on ART and episodes of low adherence (≤60%) 
declined from earlier (1999) to later years (2008) (121). A study from the Veterans Aging Cohort 
Study (VACS) in the USA also found a slight improvement in the number of patients with ≥95% 
adherence, from 37% to 42%, over a ten year study period (72). In an analysis conducted in separate 
MSM and IDU cohorts, also in the USA, self-reported adherence increased 11% and 14% every two 
years in each cohort respectively (213). Notably, in both cohorts, alcohol users, and those with active 
IDU and substance abuse were less likely to report ≥95% adherence (213). Adherence in the Swiss 
HIV Cohort study (SHCS) also showed improvement over a six year study period with the proportion 
of patients with 100% self-reported adherence increasing from 70% to 83% by study end, although 
only approximately half of the cohort reported maintaining 100% adherence throughout the study 
duration (42). Interestingly, a separate analysis on patients originating from SSA within the SHCS 
found these patients reported poorer adherence and had an increased risk of virological failure 
compared to their European-born counterparts (141). Studies in Netherlands also reported SSA 
patients on ART had lower ARV plasma concentrations and were at greater risk of virological failure 
compared to indigenous Dutch patients (214, 215). Socioeconomic factors such as immigrant status, 
unemployment, unstable housing, cultural barriers and lack of support structures may present as 
adherence barriers in this patient group.  
Poor long term adherence in developed countries has been associated with female gender, younger 
age, belonging to an ethnic or race minority, active substance abuse, alcohol abuse, depression, prior 
episodes of virological failure, high pill burden, use of unboosted PI inhibitor regimens, dosage 
frequency of more than twice a day and lack of partner support (43, 121, 132, 211, 212). 
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There is a paucity of literature on long term adherence in African populations. One cohort in which 
long term adherence has been extensively investigated is the Senegalese Antiretroviral Access 
Initiative where patient adherence was assessed by self-report and pill count over 7 years. The 
proportion of patients with optimal adherence (≥ 95%) declined in the initial four years of follow up 
but adherence levels stabilised above 71% after the fourth year (216). The overall mean adherence 
was 91% and three quarter of patients had optimal adherence levels at the end of the study period 
(216). There was substantial variability in patient level adherence over time with three average 
adherence patterns characterised: consistently high adherence, declining initial adherence that 
increased over time, and high initial adherence that declined over time thus demonstrating the 
changeability in long term adherence behaviour (133, 217). Women were found to have 37% greater 
chance of achieving ≥95% adherence compared to men, whereas patients on an Indinavir (IDV) based 
regimen had a 30% lower adherence compared to those on NNTRI based regimens (133).  
A large cohort study in Nigeria found that in over 5500 patients on ART for more than five years, 
more than 80% of patients demonstrated adherence levels ≥95% measured by pharmacy refill (218). 
Patients who had consistently higher adherence during the first three years after ART initiation were 
less likely to withdraw from treatment, be lost to follow up or die (218). 
Meresse et al. (219) reported that 75% of patients in a multicentre study in Cameroon had ≥80% 
adherence in the 12-24 month period after ART initiation. This study also demonstrated the shifting 
nature of adherence behaviour over time as a quarter of patients who had optimal adherence during 
the first six months after starting treatment had a least one episode of either non-adherence or 
interruption of treatment in the second year. Eighty percent of patients who were non-adherent or had 
treatment interruptions in the initial 6 months of treatment became adherent in the maintenance 
treatment phase. The odds of non-adherence in men was double compared to women, while patients 
who were non-adherent in the first 6 months after starting ART had a seven times greater risk of 
virological failure.  
Botswana was the first SSA country to provide free public access to ART. Results from a five year 
follow up of 633 patients initiated on ART in 2002, 60% of whom were female, found a 92% overall 
mean adherence by pharmacy refill (220). Only a minority of patients, just over 10%, had ever missed 
two or more refill visits in a year (220). Although not used to assess adherence in this study, 
pharmacy pill counts were conducted at each visit and patients were counselled accordingly. 
El-Khatib et al. (27) reported 94% of patients in a South African cohort, on ART for a median of 3.7 
years, had ≥95% adherence determined by pharmacy refill visits. The main patient reported reasons 
for non-adherence were being away from their home, forgetting and being busy with other 
responsibilities (27). Patient characteristics, socioeconomic and clinical variables did not impact on 
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adherence but a significant association was found between cumulative drug refill adherence of <95% 
and an increased risk of virological failure. 
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 Table 1: Summary of long-tern ART adherence literature 
Year/ 
Country/Study 
setting 
Study 
Design 
Sample 
size, n 
Age, years Gender, 
male % 
Duration 
of follow 
up, years 
Adherence 
Measure 
Period of adherence 
assessment  
Optimal 
Adherence, 
% 
Proportion 
of cohort 
with 
Optimal 
Adherence  
Proportion of 
cohort virally 
suppressed 
USA & European Studies 
2006, Italy  
Single centre, hospital 
clinic (211) 
 
CS 171 41.2* 67.3 3*  SR, PR SR – 3 month recall,  
PR – quarterly 
review 
≥90 NR 47% 
2006, France 
multicentre, clinics 
(123) 
CS 1110 37† 78 5 SR  previous 4 days  100 63% 58% 
2007, USA  
Multicentre study (43) 
CS 640a 
 
1304b 
44.1*a 
 
38.8*b 
33 5 SR previous 3 or 4 days 100 77% NR 
2009, Canada 
Multicentre, health 
facilities (35) 
 
CS 903 41† 79 2.75† PR 6 month intervals ≥95 72% NR 
2009, France 
Multicentre, clinics 
(212) 
 
CS 1010 38.9*  78.5 10 SR previous 4 weeks  100 26% NR 
2009, Spain 
Single centre, hospital 
clinic (28) 
 
CS 540 36.25† 69 8.3†  SR, PR SR – previous 
month;  
PR – previous two 
months 
>90 62% 59% 
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Year/ 
Country/Study 
setting 
Study 
Design 
Sample 
size, n 
Age, years Gender, 
male % 
Duration 
of follow 
up, years 
Adherence 
Measure 
Period of adherence 
assessment 
Optimal 
Adherence, 
% 
Proportion 
of cohort 
with 
Optimal 
Adherence 
Proportion of 
cohort virally 
suppressed 
2010,  
United Kingdom 
Single centre, clinic 
(121) 
 
CS 2060 41† 78 4.5† PR  6 months  ≥95 51% NR 
2010, Switzerland 
Multicentre, clinics 
(42)  
CS 6709 41† 69.6 4.5† SR previous 4 weeks  100 83% NR 
2015, USA 
Multicentre, health 
facilities (72) 
CS 21 865 45.7*  98 10 MPR yearly ≥95 42% 92% 
2015, USA 
Multicentre, health 
facilities (213) 
 
CS 1006a 
197c 
49.2*a 
49.8*c 
100a 
67.8c 
 
10 SR 4 daysa 
3 daysc 
≥95 90%a 
92%d 
79.9a 
65.6c 
2017, Canada 
Multicentre, health 
facilities (132) 
CS 4534 women:38† 
men:42†  
80.1 5.5†  PR 6 month intervals ≥95 women - 
57.0%       
men –77.1% 
NR 
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Year/ Country/Study 
setting 
Study 
Design 
Sample 
size, n 
Age, years Gender, 
female 
% 
Duration 
of follow 
up, years 
Adherence 
Measure 
Period of adherence 
assessment 
Optimal 
Adherence, 
% 
Proportion 
with 
Optimal 
Adherence 
Proportion of 
cohort virally 
suppressed 
African Studies 
2007, Senegal 
Single centre, 
hospital clinic (216) 
 CS 158 38† 50 6.5* PC  previous 30 days ≥95 73.7% NR 
2008 Botswana  
Multicentre, clinics 
(220) 
 CS 633 34.8†    60 3.5†  PR 30 days >90 73.7% 98.3% 
2011, Senegal  
Single centre, 
hospital clinic (133) CS 330 37†  56 7.6†  PC, SR previous 30 days ≥95 74.8% NR 
2011, South Africa 
Single centre, clinic 
(27) 
 CS 456 NR 77 3.7† PR cumulative ≥95  94% 81% 
2013, Cameroon 
Multicentre, hospital 
clinics (219) 
 CS 254 37* 70.5 2 SR 
previous 4 days & 
previous 4 weeks ≥80 71.2%  58% 
2015, Senegal 
Single centre, 
hospital clinic (217)  CS 317 37.5*  55 7.7† PC  previous 30 days >95 69% NR 
CS = cohort study     NR = not reported   a MACS - Multicenter AIDS Cohort Study 
PC = pill count     MPR = medication possession ratio  bWHIS - Women’s Interagency HIV Study 
SR = self-report     ᵻ median     c ALIVE AIDS Linked to the Intravenous Experience study 
PR = pharmacy refill    *mean 
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Long term adherence has been assessed over lengthier time periods in USA and European cohorts 
than in African studies. This is explainable by the fact that ARVs became available in developed 
countries approximately two decades earlier than in most developing countries, therefore, patients 
from developed countries have been exposed to ART for longer. The exception is the Senegalese 
Initiative Sénégalaise d’Accès aux Antirétroviraux (ISAARV) cohort, where patients had access to 
ART as early as 1998 and duration of follow up is longer (7 years) compared to other African cohorts. 
However, ART has been available for more than a decade in Africa and there is an evident lack of 
data on long term adherence in African patients with only six studies identified in the literature 
review, three of which are from the ISAARV cohort, and only one study in South Africa. There are 
several well defined observational cohorts of PLWH on ART in developed countries that report on 
adherence and patient outcomes including SHCS, APROCO, VACS, MACS, WIHS and 
Antiretroviral Therapy Cohort Collaboration (ART-CC). A similar effort is lacking and much needed 
in Africa and other developing nations where the burden of HIV is highest.  
Patients in USA and European cohorts were treated with early era ART regimens consisting of 
various unboosted and boosted PI based regimens whereas treatment regimens in African studies are 
standardized once daily NNRTI-based regimens using either EFV or NVP. Early era ART regimens 
had a higher pill burden, required more than once daily dosing, were prone to side effects and toxicity, 
all factors which may impair adherence (178). A number of studies found PI regimens were 
associated with poorer adherence; Knobel et al. (28) reported a two-fold higher risk of non-adherence 
for patients on unboosted PI regimens, 40% of patients on unboosted PI regimens had worsening 
adherence and 38% had poor adherence in the SHCS, and a PI regimen was also associated with 
suboptimal adherence in the ISAARV, APROCO, MACS and VACS cohorts (42, 43, 72, 212, 216). 
Moreover, studies have reported that patients initiating ART in later calendar years demonstrated 
better adherence. For instance, in the SHCS only a third of patients initiating ART in 2003 had perfect 
adherence but the proportion of adherent patients increased in each subsequent year of ART initiation 
with 78% of patients initiating ART in 2012 reporting no missed doses (42). Puskas et al. (132) 
reported patients initiating ART in the 2000-2004 year period were 40% less likely to be adherent 
compared to patients who started ART in 2008 and after. Similarly, in the VACS cohort there was a 
16 % increase in adherence from 2001-2005 to 2006-2011 (72). Phasing out of unboosted PIs, 
introduction of fixed drug dose combinations and availability of newer, better tolerated ARV drugs, 
such as integrase inhibitors, may account for improved ART adherence in patients in more recent 
years. Due to the later introduction of ART in Africa, patients were not exposed to the afore-
mentioned adherence barriers associated with early era ART regimens and the use of standardized 
regimens and fixed drug combinations may have assisted patients to achieve optimal adherence.  
Adherence measures selected for assessment in long term adherence studies should ideally be low 
cost, easy to implement, adaptable to different settings and be able to conduct over long follow up 
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periods; self-report and pharmacy adherence measures (pill count and pharmacy refill) fulfil these 
criteria well. Indeed, self-report was the most frequently used adherence measure in USA and 
European countries followed by pharmacy refill (28, 42, 43, 123, 211-213). Varying time periods 
were used to assess self-reported adherence from the previous 3-4 days up to 1-3 months. While it 
may be easier for patients to provide more accurate responses for a shorter recall period, non-
adherence before this time period would be missed. Recall periods of up to 4 weeks or longer may be 
inaccurate if patients are unable to remember adherence information over the past month/s. In African 
studies, pharmacy adherence measures were mostly used to assess long term adherence (27, 133, 216, 
217, 220). Overall, only three studies used a combination of both these measures to calculate 
adherence (28, 133, 211). As discussed previously, pharmacy refill may underestimate adherence, for 
example, if patients collect a refill late but have extra pill doses available and can overestimate 
adherence if a patient collects a refill early. Although viral load is considered the benchmark for 
adherence monitoring less than half of all the studies reviewed reported viral load outcomes and it 
was not possible to correlate long term adherence measures in these studies with viral suppression and 
patient outcomes. 
In summary, there is much variability between long term adherence studies with respect to sample 
populations, cohort sizes, duration of follow up and assessment of adherence. Patients in long term 
adherence studies in USA and Europe tend to demonstrate lower adherence than their African 
counterparts. A limitation in many studies is the lack of viral load monitoring making it challenging to 
determine if the adherence measure used is predictive of virological outcomes. There is a scarcity of 
literature on long term adherence in Africa and particularly South Africa, which has the largest 
number of people on ART in the world. This knowledge can assist in identifying patient groups 
vulnerable to poor adherence and determining where limited resources should be invested in strategies 
to improve adherence in long term ART care.  
1.3 Problem statement and study significance  
Near perfect levels of adherence to ART are required to achieve durable viral suppression, prevent 
drug resistance and improve morbidity and mortality outcomes in PLWH. Early studies in Africa 
found patients were able to achieve good rates of optimal adherence, however, much of this data is 
from early treatment programmes that provided access to limited ART regimens. As ART scale up 
continues and treatment programmes expand it remains unknown whether these early promising 
adherence rates will be sustained over the long term.  
Sub-Saharan Africa has the largest number of PLWH. ART adherence studies in this region have 
focused on ART naïve patients initiating treatment, adherence within the first year or two post-
initiation or adherence at a single point in time (cross-sectional studies). There is a lack of published 
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data on long term ART adherence in this region, particularly in South Africa, which has the largest 
number of people on ART in the world. 
The cohort of patients studied were on ART for at least five years or longer. It is postulated that 
patterns and predictors of adherence assessed over this length of time can provide new insights into 
adherence behaviours in our population setting and help to inform sustainable and effective adherence 
interventions.  
While adherence support is advocated by local ART guidelines, there is no standardized method of 
adherence monitoring in the resource limited South African health care setting (83). Although viral 
load is considered the benchmark for monitoring treatment response it is only measured annually in 
routine HIV care (83). Thus, patients with poor adherence may be identified at a stage where it could 
be too late to avoid resistance to first line treatment and treatment failure. Examining the relationship 
between long term adherence by pill count and viral load may help determine if pill count can be used 
as a reliable method for adherence monitoring when viral load monitoring is infrequent or expensive. 
Pill count was selected as the measure of adherence for this study as it was identified as a more 
objective adherence measure than self-report and is cost-effective in a resource limited setting. In 
addition, ARV doses lost and reported at home are also taken into consideration to provide a more 
accurate adherence assessment which is not possible with pharmacy refill adherence assessments.  
Providing patients with more than one month supply of ART at a time can ease clinic loads and 
waiting times at public health facilities and save patients time and money spent on monthly clinic 
visits to collect ART. Understanding adherence in patients who received an extended three month 
supply of ARV medication may provide evidence to support provision of more than a month’s supply 
of treatment at a time to the benefit of patients and the overburdened health care system.  
TB is the most common opportunistic infection in PLWH in South Africa. High pill burden and 
overlapping side effects (rash, gastrointestinal side effects, hepatotoxicity and peripheral neuropathy) 
associated with concomitant HIV and TB treatment may hinder adherence to ARV medication. We 
investigated if there were any changes in ART adherence in patients with recurrent TB during HIV 
and TB co-treatment.  
1.4 Research Questions 
 Are there identifiable patterns or trends in long term ART adherence in adult patients ≥18 
years?  
 What patient factors are associated with optimal (≥95%) and sub-optimal (<95%) adherence 
in HIV positive adults on long term ART (≥5 years)?  
 What is the relationship between pharmacy pill count and viral load in HIV positive adults on 
long-term ART (≥5years)? 
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1.5 Aim and Objectives 
1.5.1 Aims   
The aim of this project was to retrospectively assess long term adherence in HIV infected patients on 
ART in order to inform long term care. 
1.5.2 Objectives 
The aim of the study was achieved through the objectives listed below. 
I. Assess and compare adherence by pill count and viral load data.  
II. Determine if baseline patient and socio-demographic variables predict long term adherence 
behaviour. 
III. Determine the effect of ARV regimen change on adherence by assessing pill count and viral 
load data six months before and after switch to a second line treatment regimen. 
IV. Assess ART adherence during episode/s of recurrent TB treatment by pill count and viral load 
data. 
V. Determine if there are differences in adherence by pill count between patients receiving a 
monthly versus three monthly ART supply. 
1.6 Conceptual Framework 
There are 5 key factors that can influence medication adherence – patient factors, treatment factors, 
disease factors, socioeconomic conditions and health care systems (Figure 1) (44). In the literature 
review all five groups were identified as determinants of ART adherence.  
 
                         Figure 1: Factors influencing ART adherence 
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 Patient factors 
Demographic variables such as age, gender and race have shown inconsistent results in relation to 
adherence although age and gender do appear to play an influential role in some settings, with female 
gender and younger age associated with poor adherence (113, 120, 129, 135, 136). Alcohol abuse, 
current substance abuse and depression are important barriers to adherence (142, 149). Non-disclosure 
of HIV status, lack of social support structures and stigma also have associations with adherence 
challenges (154, 156). Patient related adherence barriers may the most modifiable and much focus is 
centered on these issues in interventions to improve adherence. 
 
Patient variables that were investigated in this research analysis included age, gender, marital status, 
number of children, and HIV disclosure. 
 Socio-economic factors 
Level of education, employment, living conditions and poverty have been reported to affect adherence 
although less so in developed countries. The effect of poor socioeconomic status on adherence is more 
evident in resource limited settings where food insecurity, unstable housing, unemployment and 
financial constraints present significant barriers to adherence (135, 167-169). 
 
Socio-economic variables that were investigated in this research analysis include: employment, 
education, living conditions and household status. 
 Treatment factors 
Adherence to a stringent dosing schedule and dietary restrictions together with complex regimens and 
a high pill burden are a challenge for many patients (37, 171, 172). Side effects, particularly those that 
cause changes in appearance (lipodystrophy) or affect daily quality of life (neuropathy) further impact 
on adherence (44, 178, 179).  
Treatment related variables that were investigated in this research analysis include ART regimen and 
pill burden. 
 Disease factors 
Adherence to therapy for chronic conditions had been shown to be as low as 50% and HIV is no 
exception despite the more immediate threat of morbidity and mortality(44). The need for life-long 
therapy can lead to treatment fatigue and non-adherence (189, 190). In asymptomatic patients 
motivation to adhere may be reduced (182). The presence of co-morbid conditions or opportunistic 
infections can increase pill burden and impair adherence to ART. 
Disease factors that were  investigated in the study are the effect of concurrent ART and TB treatment 
on ART adherence in HIV and TB co-infected patients. 
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 Health care system 
The nature of the patient-provider relationship, access to treatment facilities, user costs for health care 
services, availability of trained health care personnel and quality of service provided have been shown 
to influence adherence (124, 135, 198). A breakdown in any of the aforementioned health system 
factors may negatively affect patient adherence whereas as a well-functioning healthcare system can 
assist patients to improve and maintain treatment adherence.  
We did not investigate the relationship between adherence and the health care system in this study. 
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CHAPTER 2: METHODS 
2.1 Study Design 
2.1.1 Setting 
This was a retrospective cohort study assessing long-term ART adherence in patients who were 
initially enrolled in a randomised controlled trial studying TB and HIV treatment integration and 
subsequently followed up in an observational cohort study on TB recurrence. Both studies were 
conducted by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) at the 
CAPRISA eThekwini Clinical Research Site (CRS) located in Berea, Durban, Kwa-Zulu Natal, South 
Africa. The Kwa-Zulu Natal province has the highest HIV prevalence (16.9%) in the country (4). 
Within the province, the eThekwini district, which encompasses Durban and surrounding areas, has 
the second highest HIV prevalence (16.8%) from all metropolitan areas in Kwa-Zulu Natal (221).  
Study participants were recruited from the Prince Cyril Zulu Communicable Diseases Centre 
(PCZCDC) located adjacent to the CAPRISA eThekwini CRS. The PCZCDC is one of the largest 
public health TB and sexually transmitted infection (STI) clinics in the province, situated near the 
major transport hub in the Warwick Triangle area and is accessed by thousands of patients from 
across the larger Durban area. 
Antiretroviral treatment was provided to study participants through the CAPRISA AIDS Treatment 
programme funded by PEPFAR. Access to ART from public health facilities in South Africa was 
limited at the time. 
2.1.2 Sample population 
The Starting Antiretroviral Therapy at Three Points in Tuberculosis (SAPiT) study was an open label 
randomized control trial that compared three treatment strategies of ART initiation in HIV and TB co-
infected patients (N=642) (222). Participants were enrolled between June 2005 and July 2008. The 
primary objective of the study was to determine the optimal time to start ART in an HIV and TB co-
infected patient. The standard duration of treatment for pulmonary TB in the study was six months; a 
two-month initiation phase followed by a four-month continuation phase. Eligible male and female 
adults, 18 years and older, were randomly assigned to initiate ART either within one month of starting 
TB treatment, or within one month of completing the initiation phase of TB treatment, or within one 
month of completing the continuation phase of TB treatment. Study patients were initiated on a once-
daily, weight-based ART regimen containing EFV or NVP plus lamivudine (3TC) and enteric coated 
ddI. 
TB Recurrence upon Treatment with HAART (TRuTH) was a prospective cohort observational study 
investigating the rate of TB recurrence in HIV infected adult patients who had completed pulmonary 
TB therapy and were on ART (N=402). This cohort was comprised of participants from the completed 
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SAPiT study who were then offered enrolment into the TRuTH study (223). Ex-SAPiT study patients 
were enrolled into the TRuTH observational study from November 2009 to July 2011 and follow up 
was completed in April 2014. 
All patients received three pre-ART education counselling sessions that provided information on HIV 
disease, an introduction to ART, individual ARVs in the treatment regimen, ARV side effects and the 
importance of maintaining optimal adherence to treatment. Ongoing general adherence support post-
ART initiation was provided by trained counsellors and site pharmacists in both studies. In addition, 
pharmacists were involved in targeted adherence counselling to patients who were identified with 
suboptimal adherence by pill count. Pharmacists also provided pillboxes to all patients as an 
adherence aid. To assist patients in using the pillbox and ensure they understood how to take their 
daily ART dose, patients were requested to fill the weekly pillbox in the presence of the pharmacist or 
counsellor at ART initiation or if there was a change to their ART regimen. Additionally, in patients 
identified with ongoing adherence challenges, the pharmacist would pack and provide pillboxes with 
a full month supply of ART to facilitate adherence. Patients that missed their scheduled clinic 
appointment date were telephonically and/or physically tracked. Treatment supporters, where 
possible, were enlisted to provide additional support for patients identified with adherence challenges. 
Inclusion and Exclusion Criteria 
Inclusion criteria: 
Participants who were enrolled, initiated on ART, completed follow up in the SAPiT trial and then 
subsequently joined the TRuTH cohort study were selected for inclusion. In addition, participants had 
to be on ART for at least five years from the time of ART initiation in SAPiT to study exit in TRuTH.  
Exclusion criteria: 
Participants who were lost to follow up in SAPiT, did not collect their ARV treatment from the 
research site pharmacy and for whom pill count data was missing for more than 6 consecutive months 
were excluded.  
A biostatistician was consulted to determine the sample of patients from the afore-mentioned studies 
eligible for inclusion in the retrospective study. The sample size (N=270) was deemed adequate for 
the proposed statistical analysis (refer section 2.4) 
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Figure 2: Selection of patient cohort on ART for at least 5 years 
 
2.2 Data Collection 
In both the above-mentioned studies validated paper case report forms (CRFs) were used for 
recording participant-specific quantitative data at each study visit. The CRFs provided a standardised 
tool for recording information thereby improving data reliability. On enrolment into each study, 
participants were assigned a unique patient identification number (PID) provided by the study Data 
Management Centre. This PID was used to identify the participant on each CRF completed at every 
study visit for the duration of the study. The paper CRF’s were filed together with other study 
documents including clinical chart notes, laboratory results and prescription cards in participant-
specific study files stored at the research site.  
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To ensure content and construct validity, the CRFs were created, revised and updated by the 
CAPRISA Data Management centre in consultation with the protocol team, including the study 
pharmacist. The CRF content and questions were dependant on the type of information required to be 
recorded.  
Further measures to improve data validity and reliability included the use of validated equipment for 
viral load and CD4 measurements, training of study staff on the correct procedures for CRF 
completion, CRFs were checked for completeness by a member of the Data Management team before 
uploading to the CAPRISA electronic database and quality control (QC) reports were generated once 
the data was uploaded. Any incorrect or invalid data entries identified on a QC report were corrected 
and resolved on the original CRF and re-captured on the electronic database. 
Baseline demographics and behaviour variables captured at the SAPiT study enrolment visit included 
age, gender, household status, marital status, occupation, education, number of children, basic living 
conditions, HIV testing and disclosure. At ART initiation, the prescribed drug regimen, dosage and 
treatment start date was captured. Any changes in ARV treatment were similarly documented. Pill 
count data, which included quantity dispensed and returned, was captured at each scheduled and 
unscheduled study visit were ARV treatment was dispensed in both the SAPiT and TRuTH studies.  
In the SAPiT trial, viral load (Cobas® Amplicor HIV-1 Monitor, version 1.5, Roche) and CD4+ cell 
count (FACSCalibur™, Becton Dickinson) measurements were performed at the time of screening, at 
randomization, and thereafter 6 monthly. Viral load (Cobas® Ampliprep-Roche TaqMan®) and 
CD4+ cell count measurements (Becton Dickinson FacsCalibur™) were performed at least 6 monthly 
in the TRuTH study. Additional viral load testing would have been conducted if requested by the 
study clinician. Viral load measurements were recorded on appropriate CRFs.  
Adherence to ART during recurrent TB episodes in the TRuTH study were determined by using 
documented TB treatment start and stop dates. 
Table 2: SAPiT CRF Data 
Plate # Data Captured Variables Appendix 
001 
002 
Demographics  Age, Gender, Household status, 
Primary breadwinner, Marital status, 
Occupation, Education, No. of 
children, Living conditions 
D 
003 Baseline Behaviour 
Questionnaire  
HIV testing, HIV disclosure E 
018 HIV Bloods Viral load and CD4+ cell counts F 
020 ARV Treatment ARV drug, dosage, duration of use G 
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Plate # Data Captured Variables Appendix 
024 
063 
Pill Count Number of tablets lost, remaining, 
returned and dispensed 
H 
030 
031 
WHO Staging WHO Clinical Stage 1,2,3, and 4 
disease 
I 
057 Termination from study Completion of follow up in study J 
 
Table 3: TRuTH CRF Data 
Plate # Data Captured Variables Appendix 
018 HIV Bloods  Viral load counts K 
055 TB Treatment Date of TB treatment initiation and 
completion  
L 
063 Pill Count Number of tablets lost, remaining, 
returned and dispensed 
M 
057 Termination from study Completion of follow up in study N 
 
2.3 Data Management 
Data captured in both studies was stored in a secure electronic database. CRFs selected for analysis 
where based on data relevant to the aim and objectives of the study. The required variables were 
downloaded and provided by the data manager (Table 1 and 2). In the event of incorrect, incomplete 
or missing data being identified, a file review was done to locate the original paper CRF for 
verification. Corrections made to a CRF were checked by the data manager before the CRF was re-
entered into the database with the updated information. Where CRF data was unavailable, other 
source documentation (chart notes, laboratory results, prescriptions) were reviewed to obtain the 
required information. The data checks, file reviews, CRF corrections and final data set for analyses 
were completed by the Masters candidate. 
2.4 Data Analysis 
Baseline demographic data were obtained on enrolment into the SAPiT trial and were analysed by 
descriptive statistical methods. Continuous variables are reported as mean with standard deviation 
(SD) or median with inter-quartile range (IQR). Categorical variables were reported as percentages or 
frequencies. 
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Table 4: Variables for analysis 
Variable Type of 
variable 
Descriptive Measure 
Age 
Viral load 
CD4 
Continuous median, IQR 
Gender 
Education 
Household status 
Primary breadwinner 
Marital status 
Occupation 
Living conditions 
Number in household 
HIV disclosure 
WHO Staging 
Categorical 
(Nominal) 
Number, Percentage 
Adherence (pill count) Continuous Mean, SD 
 
Undetectable viral load was defined as <400 copies/mL. In the SAPiT trial, treatment failure was 
defined as two HIV-1 RNA measurements of >1000 copies/mL taken at least 4 weeks apart followed 
by ART discontinuation and switching to a second-line ART regimen consisting of a boosted PI plus 
two NNRTIs. In the TRuTH study treatment failure was defined as two consecutive HIV-1 RNA 
measurements of >1000 copies/mL at least six months apart followed by a switch to a second line 
regimen consisting of a boosted PI plus two NNRTIs. 
Adherence to ARV treatment in both studies were determined by pharmacy pill counts. This was 
assessed at least monthly in the SAPiT trial and either monthly or up to three monthly in the TRuTH 
study depending on the quantity of ART dispensed. Optimal adherence was defined as ≥95% of doses 
taken and poor adherence as <95% of doses taken in the specified time period. Adherence percentage 
was calculated using the following formula: 
No. of tablets dispensed at previous visit – Number of tablets returned/ reported remaining/lost at current visit       x 100 
Number of tablets that should have been ingested between visits (daily tablet dose x no. of days between visits) 
Adherence values were not calculated for visits where a clinician-initiated treatment interruption had 
been instituted or pill count data was missing e.g. tablets not returned and reported remaining or lost 
was unknown.  
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Mean pill count adherence for a given period was calculated as the weighted mean of the monthly 
and/or three monthly adherence values from the period, where the weights were calculated as the 
length of time between each visit (i.e. one month or three months). Chi-square tests (α =0.05) were 
used to determine the association between patient baseline characteristics and optimal adherence over 
the study period. Sensitivity and specificity values (and associated 95% confidence intervals) were 
calculated for each year on ART to assess the extent to which mean pill count adherence over the year 
could be used to identify patients who were virally suppressed by year end. The Wilcoxon signed rank 
test (α =0.05) was applied to the adherence values and viral load before and after switch to a second 
line regimen in patients with treatment failure as well as to adherence values and viral load before and 
after the start of TB treatment following TB recurrence. A Kaplan Meier survival analysis was used to 
estimate time to treatment failure.  
Statistical Analysis System (SAS) version 9.4 software was used to conduct statistical analysis. 
2.5 Ethical considerations 
The completed SAPiT and TRuTH studies were approved and conducted under the oversight of the 
Biomedical Research Ethics Committee at the University of KwaZulu-Natal [SAPiT (E107/05) and 
TRuTH (BF051/09)]. Participants in both studies provided written informed consent. Informed 
consent forms for both studies described the purpose of the study, study procedures to be conducted at 
each study visit, and the risks and benefits of study participation. The informed consent forms were 
also available in isiZulu for participants whose first language was isiZulu. Study participants were 
reimbursed a nominal amount for each study visit for time spent at the clinic. To ensure 
confidentiality all participant data has been anonymised by the removal of personal identifiers.  
In this retrospective study of SAPiT and TRuTH data, there was no direct participant contact and 
informed consent was not required as it had been provided when participants joined the SAPiT and 
TRuTH  studies. Ethics Approval for this retrospective study was received from the Biomedical 
Research Ethics Committee at University of KwaZulu-Natal (BE046/16). 
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ABSTRACT 
South Africa supports the largest antiretroviral therapy (ART) programme globally and recently 
introduced universal test and treat (UTT). Maintaining optimal ART adherence (≥ 95%) is essential 
for successful patient and public health outcomes. Long-term adherence to ART (≥5 years) was 
retrospectively analysed in tuberculosis (TB) and HIV co-treated patients in Durban, South Africa. 
Adherence was comparatively assessed using pill count and viral load data. From an initial cohort of 
642 participants, 270 participants were included in the analysis; 54.8% were female, median age was 
34 years (IQR:29-40) and median time on ART was 70 months (IQR=64-78). Mean ART adherence 
was ≥95% for each year on ART and 94% of patients were virologically suppressed at the end of 
follow-up. Pill count showed high sensitivity (95%; 95%CI:91-98%) in predicting viral suppression 
but poor specificity (9%; 95%CI:0-41%) for predicting detectable viral loads at 5 years post-ART 
initiation. However, half of all patients had at least one sub-optimal (<95%) pill count in the first six 
months after ART initiation and <20% between the first and sixth year. Viral suppression was 87.4% 
six months after ART initiation and increased thereafter, remaining >92% throughout follow-up. HIV 
and TB co-treatment, switching to second line ART with higher pill burdens and providing an 
extended ART supply in clinically stable patients did not impair ART adherence. Optimal long-term 
adherence with successful treatment outcomes are possible within a structured ART programme with 
close adherence monitoring. This adherence support approach and these findings are relevant in the 
era of UTT. 
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INTRODUCTION 
Currently, an estimated 36.7 million people are living with HIV (PLWH) worldwide. 1 Sub-Saharan 
Africa (SSA) has the largest global HIV burden of infection with prevalence at 4.2% and an estimated 
3200 new infections occurring daily. 1, 2 Within this region, South Africa is the country with the 
highest adult HIV prevalence (18%) and has the largest adult population of PLWH in the world, 
estimated to comprise approximately 7.5 million people. 3, 4 The country’s government funded 
national antiretroviral (ARV) rollout programme is the largest globally, providing antiretroviral 
treatment (ART) and care to over four million people. 5 In September 2016, South Africa incorporated 
the universal test and treat (UTT) policy into its’ national ART guidelines. 6 With the implementation 
of this policy, the number of HIV infected individuals eligible to start ARV treatment has escalated 
substantially.7 
Access to ART is only one aspect of an effective HIV management programme. Early studies 
reported that successful antiretroviral therapy required adherence to daily dosing of ≥95% to achieve 
and maintain viral suppression. 8, 9 However, more recent studies have shown that virologic 
suppression may still be achieved with <95% adherence levels but this is dependent on the ART drug 
combination used, time on ART and previous exposure to ART. 10, 11 Furthermore, repeated adherence 
levels of <100% and treatment interruptions are associated with an increased risk of nucleoside 
reverse transcriptase (NRTI) and non-nucleoside reverse transcriptase (NNRTI) resistance which form 
the backbone of current first line ART regimens in South Africa. 12-14 Thus, although NNRTI and 
boosted protease inhibitor (PI) regimens may be more robust despite imperfect adherence it is still 
recommended that ≥95% adherence be maintained to achieve optimal viral suppression and prevent 
emergence of resistant virus. 15, 16 
Early adherence studies found a comparatively high proportion  of African patients were able to 
achieve optimal adherence to ART.17-19  In South Africa, short term ART adherence rates (less than 
two years from treatment initiation) in patients from multiple urban HIV clinics is reported to range 
from 63 to 88%, however, there is a paucity of information on long-term adherence in this population. 
20-23 As treatment programmes continue to expand, and patients become more treatment experienced, 
determining adherence patterns over the long-term can provide insight into observed treatment 
outcomes and assist in developing appropriate adherence support and intervention strategies. The  aim 
of this study  was to address this knowledge gap by assessing long-term adherence in patients on ART 
for at least five years in an urban research clinic in Durban, South Africa.  
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METHODS 
Study Design, Setting and Patients 
This is a retrospective analysis of long-term ART adherence in HIV infected, ART-naïve patients who 
were originally enrolled in a randomised controlled trial assessing tuberculosis (TB) and HIV 
treatment integration and followed up in an observational cohort study assessing TB recurrence at the 
Centre for the AIDS Programme of Research in South Africa’s (CAPRISA) eThekwini Clinical 
Research site in Durban, South Africa.  
Initially, HIV and TB co-infected patients were enrolled in the Starting Antiretroviral Therapy at 
Three Points in Tuberculosis (SAPiT) open label randomised controlled trial from June 2005 to July 
2008 (n=642). Details of the study outcomes have been published elsewhere. 24, 25 Study patients were 
initiated on a once daily, weight-based ART regimen containing efavirenz (EFV) or nevirapine (NVP) 
plus lamivudine (3TC) and enteric coated didanosine (ddI) either during or after completion of 
tuberculosis treatment. Viral load (Cobas® Amplicor HIV-1 Monitor, version 1.5, Roche) and CD4+ 
cell count (FACSCalibur™, Becton Dickinson) measurements were conducted at screening, on 
randomization into the study and 6 monthly thereafter.  
After completion of follow up in the SAPiT trial, patients were offered enrolment into a prospective 
observational study, TB Recurrence upon Treatment with HAART (TRuTH), to investigate the rate of 
TB recurrence in HIV infected adults who had completed pulmonary TB treatment and were on ART 
(n=402). 26, 27 Viral load (Cobas® Ampliprep-Roche TaqMan®) and CD4+ cell count (Becton 
Dickinson FACSCalibur™) measurements were performed at least 6-monthly in the TRuTH study. 
Additional viral load testing was conducted if requested by the study clinician. In 2011, ddI was 
replaced by tenofovir disoproxil fumarate (TDF) in virally suppressed patients in line with WHO 
recommendations at the time. 28 Ex-SAPiT study patients were enrolled into the TRuTH observational 
study from November 2009 to July 2011 and follow up was completed in 2014.  
Long-Term Adherence                                                                                                                                          
To assess long-term adherence, all patients who were on ART for at least five years from the time of 
ART initiation in the SAPiT trial until their completion of follow up in the TRuTH study were 
included in this retrospective analysis. To maintain continuity of care, patients accessed ART after 
completion of follow up in SAPiT and before enrolment in TRuTH via the CAPRISA AIDS 
Treatment (CAT) programme at the same clinic. Pill count data was not available for ART that was 
dispensed in the CAT programme. Patients who never initiated ART, were lost to follow up in the 
SAPiT trial, did not receive  ART from the site’s research pharmacy and for whom pill count data was 
missing for more than 6 consecutive months in either study were excluded from this analysis.  
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Adherence to ART in both studies were determined by pharmacy pill counts and assessment of viral 
load data. Pill counts were conducted monthly by the study pharmacist in the SAPiT trial and either 
monthly or 3-monthly in the TRuTH study depending on the quantity of ART medication dispensed. 
Optimal adherence was defined as ≥95% of doses taken in the time between the study visits. All 
patients received pre-ART education and ongoing adherence support counselling by trained 
counsellors and site pharmacists post-ART initiation. Pillboxes were provided to all patients as an 
adherence aid. Patients who missed their scheduled clinic appointment date were telephonically or 
physically contacted. Treatment supporters, where possible, were used as additional support for 
patients identified with adherence challenges.  
Adherence percentage was calculated using the following formula:  
No. of tablets dispensed at previous visit – Number of tablets returned/ reported remaining/lost at current visit       x 100 
Number of tablets that should have been ingested between visits (daily tablet dose x no. of days between visits) 
Pill count adherence was not assessed for visits where there was a clinician-initiated treatment 
interruption or where pill count data was missing. 
The parent SAPiT and TRuTH studies were conducted under the oversight of the Biomedical 
Research Ethics Committee (BREC) at the University of KwaZulu-Natal (BREC ref: E107/05 
[SAPiT]; BF051/09 [TRuTH]). The current study is a retrospective secondary analysis of previously 
collected anonymized data from the parent studies with no direct patient contact (BREC ref: 
BE046/16).  
Statistical Analysis: 
Baseline demographic data were obtained on enrolment into the SAPiT trial and were analysed by 
descriptive statistics. Undetectable viral load was defined as <400 copies/mL. In the SAPiT trial 
treatment failure was defined as two HIV-1 RNA measurements of >1000 copies/mL taken at least 
four weeks apart followed by ART discontinuation or change of all drugs in the ARV regimen. In the 
TRuTH study treatment failure was defined as two consecutive HIV-1 RNA measurement of >1000 
copies/mL at least six months apart followed by a change to a second line ART regimen.  
Mean pill count based adherence for a given period was calculated as the weighted mean of the 
monthly and/or 3-monthly adherence values over that time period, where the weights were calculated 
as the length of time between each visit. Chi-square tests (α =0.05) were used to determine the 
association between patient baseline characteristics and optimal adherence over the study period. 
Sensitivity and specificity of the pill count based adherence estimates (and associated 95% confidence 
intervals) were calculated for each year on ART to assess the extent to which mean pill count 
adherence over the year could be used to identify patients who were virally suppressed by year end. 
The Wilcoxon signed rank test was used to analyse the impact of concurrent TB and HIV treatment on 
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ART adherence in patients presenting with recurrent TB by analysing changes in adherence and viral 
load suppression before and during TB treatment and was also applied to the adherence estimates and 
viral load before and after switching to a second line regimen to assess the impact of a change in 
regimen on adherence (α =0.05). A Kaplan Meier survival analysis was used to estimate time to 
treatment failure.  
Statistical Analysis System (SAS) version 9.4 software was used to conduct statistical analysis. 
RESULTS 
A total of 270 patients met the inclusion criteria for this analysis (Fig. 1).  The median age of the 
cohort was 34 years (IQR:29-40) and 54.8% were female (see Table 1). At ART initiation the median 
CD4+ cell count was 145 cells/mm3 (IQR:76-249) and median viral load was 141 000 copies/mL 
(IQR:37 757 – 386 000). Most patients (254/270) were classified as WHO stage 3 at baseline. A third 
of the cohort had completed secondary school, 60% were in full or part-time employment and more 
than half of all patients had disclosed their HIV status. The median duration on ART from initiation to 
completion of follow up was 70 months (IQR: 64-78). The time period between patient exit from 
SAPiT and enrolment in TRuTH (where no pill count data available) was a median of 13 months 
(IQR: 5-21). 
The majority of the cohort (94.8%) had an overall mean ART adherence of ≥95%.  Of the 14 patients 
with sub-optimal adherence, nine had adherence estimates  in the 90-95% range, two were in the 80-
90% range, two were in the 70-80% range, and only one had less than 70% adherence. There was no 
statistically significant association between baseline patient demographic or clinical characteristics 
and optimal adherence to ART (results not shown).  
Mean adherence to ART for the entire cohort was ≥95% for each year on ART (see Table 2). In the 
six months post-ART initiation, 91.8% of patients had optimal adherence. After 6 months, more than 
95% of the cohort maintained optimal adherence levels for the remainder of the follow up period. 
Adherence levels peaked (99.3%) at 18-24 months after ART initiation and remained above 98% from 
32 months onward. Half of all patients had at least one sub-optimal adherence measurement (<95%) 
in the first six months after starting ART, less than 20% between the first and sixth year and 23% after 
six years on ART. Viral suppression rates were 87.4% six months after ART initiation and thereafter 
increased and remained above 92% throughout follow up (Fig. 2). Eleven patients had a viral load > 
400 copies/mL after five years and 94% of patients were virologically suppressed at the end of the 
follow up period. Pill count showed high sensitivity in predicting viral suppression but had poor 
specificity when the viral load was detectable (see Table 3).  
Thirty-three patients from the cohort experienced  treatment failure, of whom 21 had viral rebound 
after initially being suppressed on first line ART and the remainder 12 achieved virologic suppression 
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only after switching to a second line regimen. Approximately half of all treatment failures (n=17) 
occurred within two years after ART initiation. The cumulative probability of treatment failure was 
10.7% at five years after ART initiation (Fig. 3). Adherence and viral load measurements prior to and 
after switching to a second line boosted LPV/r regimen was available for 22 of the treatment failure 
patients. The number of patients with optimal adherence improved and there was a significant 
increase in viral load suppression at 6 and 12 months after being switched to the second line regimen 
(see Table 4). 
In the TRuTH study, patients with optimal adherence by pill count and an undetectable viral load 
(n=267) were provided with an extended 3-month supply of ART at a total of 1061 study visits. 
Overall mean adherence for patients who received a 3-month ART supply was 99.5%. 
Of the 21 patients diagnosed and initiated on treatment for recurrent tuberculosis in the TRuTH study, 
three exited the study whilst on TB treatment and one did not complete their course of TB treatment. 
In the remaining 17 patients, there was a decline in optimal adherence and viral load suppression 
when patients were on both ART and TB treatment, but this was not statistically significant (see Table 
4). 
DISCUSSION            
Our study found overall high  adherence to ART in this South African cohort followed up over a 
period of more than six years. Treatment outcomes were successful on both first and second line 
treatment, with 93.9% of patients virologically suppressed at study completion and only 12% 
experiencing treatment failure over the entire follow up period. Adherence in the first year of 
treatment was higher (98%) than those reported in several African studies, where adherence estimates 
ranged from 72 to 94%. 21, 29-33 Intensive pre-ART education and counselling sessions, an ongoing 
adherence support programme post-ART initiation, provision of pillboxes and use of a once-daily 
ART regimen, support measures that have been shown to positively influence adherence, may have 
played a role in helping to attain high adherence. 34-37 A previous qualitative study in the SAPiT 
cohort showed a good patient-healthcare provider relationship,  accessible free care and routine 
remembering techniques  played an important role in motivating them to adhere to their  treatment. 38 
Additionally, enteric coated ddI was used instead of stavudine (D4T) in our first line ART regimen 
due to its better side-effect profile, thereby avoiding non-adherence and discontinuation associated 
with stavudine toxicity observed elsewhere. 39, 40  
Adherence was optimal for each year of follow up and remained stable between 98-99% over the six-
year period.  Long-term adherence studies in Botswana, Senegal and Nigeria also found comparably 
high adherence levels although in the Senegalese cohort where adherence was assessed over seven 
years, adherence dropped below 90% during the initial four years before improving and stabilising at 
91%. 41-44   
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Viral suppression rates exceeded 90% for each year throughout the observation period. Similar long-
term virologic outcomes have been reported in other low- and middle-income regions. 40, 45-49 The 
proportion of patients failing treatment was highest in the two years after ART initiation, thereafter, 
the number of treatment failures declined with each subsequent year on ART. Non-adherence by pill 
count was also most frequent in the first six months of ART in our cohort. Poor adherence in the 
initial months after ART initiation has been shown to increase the risk of virologic failure in later 
years and these early adherence lapses may be the reason for the higher number of treatment failures 
initially observed thus highlighting the importance of prioritizing adherence monitoring and support 
interventions to ensure optimal adherence from ART initiation. 21, 43, 50-52 Studies on long-term 
virologic outcomes have found the risk of viral failure decreases the longer patients remained 
suppressed on ART and may account for the declining number of treatment failures observed in our 
cohort over the years. 53-55 
Sensitivity was high, but specificity was low for the use of pill count data as a proxy for viral load 
outcomes. Whilst some studies have demonstrated an association between pharmacy adherence 
measures and virologic outcomes others have found poor agreement between the two measures. 31, 32, 
56-59 The use of different optimal adherence thresholds, timing of viral load measurements, definition 
of viral load suppression and time on ART influence the relationship results between adherence and 
virologic outcomes. 32, 58 Although we used an adherence threshold of ≥95%, viral suppression has 
been reported  in patients with 85-94% adherence on long-term ART. 60 Furthermore, whilst pill 
counts provide a more objective method of adherence assessment, patient manipulation is possible as 
non-adherent patients may discard or leave behind medication not taken and return the desired 
number of pills to demonstrate good adherence. 61, 62 Even though plasma viral suppression is possible 
with sub-optimal adherence, low-level viral replication continues in the plasma and reservoirs such as 
the central nervous system and genital tract, the long-term effects of which have not been fully 
elucidated. 10, 63 Therefore, high adherence to ART remains essential to ensuring the best clinical 
outcomes.         
Patients who were stable on ART, virally suppressed and had optimal (≥95%) adherence, were 
sometimes provided with a 3-month ART supply in the TRuTH study. A high mean adherence was 
maintained for all patients that received 3-monthly ART packages. These results provide reassurance 
that stable patients can maintain optimal adherence when provided with an extended ART supply and 
patients who successfully adhere to treatment in the first two years are ideal candidates for more than 
one month’s supply of treatment. In an overburdened public health care setting, such as South Africa, 
this practice can ease clinic patient load and reduce the need for monthly clinic visits which impact 
negatively on patient finances and employment prospects.  
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High pill burden, regimen complexity and dosing more than once a day are known to hinder 
adherence. 64 This is evidenced by lower adherence often observed with PI-based regimens. 42, 65-67 
Despite the additional pill burden and dosing frequency with switching from a once daily NNRTI-
based regimen to a twice daily LPV/r regimen, with almost double the number of pills to be taken, 
adherence was not impaired and viral load suppression improved significantly in our patients who 
failed initial treatment. The use of a boosted PI regimen, provision of enhanced adherence counselling 
to patients on the implications of treatment failure with reinforcement of the importance of good 
adherence and enlisting a treatment supporter, where possible, may account for the improved 
outcomes. 68-70 
HIV and TB co-infection rates are highest in South Africa. 71 Concurrent treatment of both diseases 
reduces morbidity and mortality; however, patients must cope with the additional pill burden and 
overlapping side effects when taking ART and TB treatment which can lead to impaired or selective 
adherence to either ART or TB medication. 25, 72, 73 We found no significant changes in ART 
adherence or viral suppression in our patients on concurrent HIV and TB treatment. This is 
commensurate with findings from other South African studies. 74 
There are several limitations to our study. This was a retrospective study of ART adherence 
conducted at a single research site and adherence behaviour may have been influenced by 
participation in a clinical trial, where patients were routinely monitored and received extensive 
adherence support and counselling. Hence, adherence in this population may not be generalizable to 
other population settings. Factors associated with adherence behaviour were limited to available 
baseline patient and clinical data. Furthermore, not all eligible patients that completed follow up from 
the SAPiT study were enrolled into the TRuTH study as they were lost to follow up, demised or 
declined participation. Assessment of adherence by pill count may be prone to bias as non-adherent 
patients familiar with the pill count assessment may ‘count tablets’ and return the required number of 
pills to show good adherence. An accurate adherence calculation is not possible for patients who did 
not bring any remaining pills back, reported lost pills and/or pills left at home. 
Optimal long-term adherence rates observed in this cohort support the evidence of high adherence 
reported in other long-term African cohorts. The durability of first line efavirenz based regimens was 
demonstrated by high viral suppression rates and low number of treatment failures. Pill count was not 
a good predictor of viral failure and viral load measurement remains the benchmark for monitoring 
treatment response. However, adherence during the six months post-ART initiation period has been 
shown to impact long-term treatment outcomes and viral load is only measured six months after 
commencement of ART per in-country treatment guidelines and thereafter annually. Therefore, we 
recommend pill count as a quick, simple measure of adherence at each visit in this critical six-month 
period to identify patients with early adherence challenges and allow for timeous intervention.  
46 
 
Provision of adherence support measures which may have assisted patient adherence included 
individual and group counselling, provision of pill boxes, treatment supporters and tracking of 
patients who missed their clinic appointment date. Pharmacists were also able to identify patients 
experiencing adherence challenges when conducting pill counts and could either provide or refer 
patients for appropriate adherence counselling. Further investigation is required into determining 
which of these adherence support measures are time and cost effective for adoption into our resource 
limited public health care setting.  We also demonstrated that providing stable patients with a 3-month 
ART supply was feasible as optimal adherence was still maintained over this extended time between 
clinic visits. This has the potential to reduce clinic workloads and  patient time and costs associated 
with monthly clinic visits  and is currently being investigated further in a randomized control trial. 75 
In summary, our study found optimal long-term adherence with good treatment outcomes are possible 
within a structured ART programme with close adherence monitoring and support. With the 
implementation of universal test and treat rapid scale up of ART provision, it is imperative that patient 
adherence is continually monitored and supported to ensure a successful ART programme in South 
Africa.  
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      Table 1: Baseline demographics and clinical characteristics 
Variable Total (n=270) 
Demographics 
  Age(years), median (IQR) 34 (29-40) 
  Gender (female) (%) 148 (54.8) 
  Educationa  
     Primary school or less (%) 58 (21.5) 
     Secondary school not complete (%) 123 (45.6) 
     Secondary school complete (%) 88 (32.6) 
  Head of household (%) 179 (66.3) 
  Primary breadwinner (%)a 190 (70.4) 
  Stable partner (%) 46 (17.0) 
  Employed, full or part time (%) 164 (60.7) 
  Access to tap water and electricity (%)a 236 (87.4) 
Tested for HIV prior to enrolment (%)b 134 (49.6) 
Disclosed HIV status (%)b 154 (57.0) 
Clinical Characteristics 
  CD4+ count (cells/mm3) *, median (IQR) 145 (75-249) 
  Viral Load (copies/mL) *, median (IQR)c 141 000 (37 757 
– 386 000) 
  WHO Stage  
    Stage 3 (%) 254 (94.1) 
    Stage 4 (%) 16 (5.9) 
IQR interquartile range, WHO World Health Organization 
a 1 missing data 
b 9 missing data 
c 4 missing data 
* measured at visit prior to or at initiation of ART  
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     Table 2: Mean adherence to ART by pill count 
 
Time on ART, 
months 
sample size, 
n 
Mean 
adherence, 
% (SD) 
≤6  268 97.7 (5.2) 
> 6-12  270 98.3 (6.4) 
> 12-18  258 99.1 (2.2) 
> 18-24  205 99.3 (1.8) 
> 24-30  115 99.0 (3.6) 
>30-36 161 98.8 (5.2) 
>36-42 201 99.2 (3.4) 
> 42-48 243 99.0 (4.8) 
>48-54 260 98.7 (5.8) 
>54-60 268 98.7 (4.3) 
>60-66 270 98.8 (4.4) 
>66-72 172 98.6 (6.5) 
>72 116 98.3 (7.5) 
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Table 3: Sensitivity and specificity of ART adherence by  
                pill count in predicting viral load suppression 
Time on ART 
(years) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI)  
1  97% (94-98) 22% (3-60) 
2       98% (95-99) 10% (0-45) 
3  97% (94-99) 33% (7-70) 
4       98% (96-100) 0 
5  95% (91-98) 9% (0-41) 
ART antiretroviral therapy 
* using 12 months of pill count data before last viral load measurement closest to year of interest   
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Table 4: ART adherence and VL suppression in HIV-TB co-infected participants and participants switched to 
second line regimen 
ART antiretroviral therapy, TB tuberculosis 
VL viral load, ART antiretroviral therapy, LPV/r lopinavir/ritonavir 
a 3 missing data  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 month period 
prior to TB 
treatment (n) 
During anti-TB 
treatment (n) 
6 month period 
prior to regimen 
change (n) 
6 months after 
regimen 
change  (n) 
12 months after 
regimen changea 
(n) 
Mean adherence      
< 95% 0 3  7  2  0 
≥ 95% 17  14  14  19  19  
p-value  0.159  0.012 0.080 
Viral load      
> 400 copies/mL  2  3 21  5  1  
< 400 copies/mL 15 14 0  16  19  
p-value  0.703  <0.05 <0.05 
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Figure 1. Selection of patient cohort on ART for at least 5 years 
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Figure 2. Patient adherence and viral load suppression over duration of follow up period 
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Figure 2 Legend: 
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Time on ART 
(years) 0 2 4 6 8 
Number at risk 270 253 244 109 0 
Number of 
treatment failures 0 17 9 5 2 
 
         Figure 3. Probability of treatment failure over time 
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3.2 Discussion of Manuscript 
The aim of this manuscript was to assess long term adherence, in patients on ART for five years or 
longer in an urban adult cohort, and addresses all five primary objectives listed in Chapter 1. Monthly 
adherence, determined by pharmacy pill count, was assessed and compared to six monthly viral load 
measurements. Sensitivity and specificity values were calculated for each year on ART to evaluate if 
pill count was a reliable predictor of virological suppression. Baseline patient and socio-demographic 
variables were assessed to determine if they were predictive of long term adherence. Changes in 
adherence was also assessed when patients were switched to a second line regimen. In addition, we 
examined the impact of concurrent TB and HIV treatment on ART adherence in patients presenting 
with recurrent TB by analysing changes in adherence and viral load suppression before and during TB 
treatment.  
Overall mean adherence to ART for the entire cohort was ≥ 95% for each year on ART. The 
proportion of patients with an undetectable viral load (< 400 copies/ml) was 87.4% six months after 
ART initiation and, thereafter, increased and remained above 92% throughout study follow up. Pill 
count showed high sensitivity in predicting viral suppression but had poor specificity when the viral 
load was detectable. There was no association between baseline patient demographics or clinical 
characteristics and optimal adherence to ART. Despite the higher pill burden, optimal adherence 
improved and there was a significant increase in viral load suppression at 6 and 12 months after 
patients were switched to a second line regimen. In patients on concurrent ART and TB treatment 
there was no significant decline in ART adherence and viral load suppression rates. Stable, 
virologically suppressed patients who were provided with an extended ART supply were able to 
maintain excellent adherence with overall mean adherence of 99.5% for all three month ART 
packages dispensed. 
This study demonstrated high long term adherence to ART over a more than five year period. 
Although pill count was not a good predictor of viral failure, monitoring adherence using pill count is 
recommended during the critical six month post-ART initiation period to identify patients with 
adherence challenges as early non-adherence has been shown to increase the risk of virological failure 
in the long term. In addition, we found that providing stable patients with a three month ART supply 
was feasible as optimal adherence was maintained over the extended time between clinic visits. 
Various adherence support strategies were employed to support patient adherence and further research 
is required into determining which of these adherence support measures are time and cost effective for 
our resource limited public health care setting. Furthermore, with the implementation of the UTT 
strategy and rapid scale up of ART, it is essential to assess adherence in the increasing number of 
patients on ART to determine if the required levels of adherence for successful ART outcomes are 
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being achieved and maintained. Supplementary data not presented in the manuscript can be found in 
Appendix O. 
3.3 Masters Candidate’s contribution to the Manuscript 
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cohort 
Authors: Moosa A, Gengiah T.N, Lewis L, Naidoo K 
Journal: AIDS Patient Care and STDs 
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CHAPTER 4: DISCUSSION 
4.1 Discussion of findings 
HIV is managed as a chronic disease requiring lifelong high adherence to ART to ensure viral 
suppression, prevent emergence of resistant viral strains and achieve good morbidity and mortality 
outcomes. The literature review presented in Chapter 1 identified the paucity of information on long 
term ART adherence in South Africa, which has the largest number of PLWH on ART globally. The 
aim of this study was to assess long term adherence in patients receiving ART for at least five years or 
longer in an HIV endemic urban setting in Durban, South Africa.  
Pill count is an objective pharmacy adherence measure that has been used in various healthcare 
settings to monitor adherence. It is quick to complete, requiring no specialized equipment and 
minimal training which is advantageous in a resource limited setting. In this study, pill count based 
adherence was assessed at each visit and compared to six monthly viral load measurements. Viral load 
is currently used to monitor treatment response, however, in the public health sector it is measured 
less frequently (annually) and results are not immediately available. In this retrospective study we 
assessed if pill count data was a predictor of virologic outcomes and may be used as a reliable proxy. 
This could allow the pharmacist or other health care workers to identify and initiate a timeous 
intervention in patients at risk of viremia and treatment failure. We also investigated other factors 
reported to influence adherence behaviour, including patient socio-demographics, ARV regimen and 
pill burden.  
The key findings from this study were determined by the objectives discussed below: 
Objective 1: Assess and compare adherence by pill count and viral load data    
Overall mean pill count adherence to ART was 98.7% in this cohort over a long term follow up period 
of more than six years. Adherence within the first 6 to 12 months of treatment was 98.3% and was 
higher than that reported in several African studies ranging from 62 to 95% (51, 71, 118, 216, 219). 
Adherence levels were maintained at ≥95% for each year of follow up and remained stable, ranging 
between 98-99% over the six-year period. Long term adherence studies in Botswana, Senegal and 
Nigeria also found comparably high levels of adherence of 93%, 91% and >95% respectively, 
although in the Senegalese cohort where adherence was assessed over seven years, adherence dropped 
below 90% during the initial four years before improving and stabilising at 91% (133, 216, 218, 220).  
Intensive pre-ART education and counselling sessions, an ongoing adherence support programme 
post-ART initiation, provision of pillboxes and use of a standardized once-daily ART regimen, 
support measures that have been shown to positively influence adherence, may have played a role in 
helping to attain high adherence in this cohort (224-226). Additionally, enteric coated ddI was used 
instead of D4T in our first line ART regimen when patients were initiated on ART in the SAPiT 
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study, due its better side-effect profile, thereby avoiding non-adherence and discontinuation 
associated with D4T toxicity observed elsewhere (218, 227, 228). 
More than 90% of patients in this cohort maintained optimal adherence throughout the follow up 
period and this proportion was higher than reported in other long term African patient cohorts where 
the proportion of patients with optimal adherence ranged between 71-75% (133, 216, 217, 220). 
Overall, studies conducted in the USA and European countries reported lower adherence rates and a 
lower proportion of patients with optimal adherence, ranging between 44 to 83% over a similar long-
term period (28, 72, 121, 123, 212). There may be several reasons for this; patients in developed 
countries have had longer exposure to ART treatment as it became available about two decades before 
developing countries, such as in Africa, were able to access treatment. As a result, these patients may 
have been on older regimens with a higher pill burden and prone to more side effects and toxicity. 
Additionally, patients exposed to early era ART may have accumulated resistance to one or more 
ARV drug classes and had to be switched to more complex treatment regimens as new ARV drugs 
became available.  
Viral load was undetectable in 87% of patients at six months and this proportion increased to 92% at 
12 months after ART initiation. Only 11 patients had a viral load > 400 copies/mL after five years on 
ART and 94% of patients were virologically suppressed at the end of the follow up period. Similar 
long term virologic outcomes have been reported from other studies conducted in South Africa, 
Botswana, Zimbabwe and the USA (27, 72, 220, 228-230). The cumulative probability of treatment 
failure was 0.16 and is consistent with treatment failure rates reported in Uganda and other sub-
Saharan cohorts (229, 231, 232). The incidence of treatment failures (n=17) were highest in the two 
years after ART initiation. After the second year, the number of treatment failures declined with each 
subsequent year on ART. Studies on long term virologic outcomes have found that the risk of viral 
failure decreases the longer patients remained suppressed on ART and this may account for the high 
number of treatment failures in the initial two years after ART initiation followed by a decline in 
subsequent years in our cohort (74, 233, 234). However, despite the improvement in viral suppression 
rates over time, poor adherence in the initial months of ART treatment (early non-adherence) has been 
shown to increase the risk of virologic failure in later years (48, 218, 219, 235, 236). This is 
commensurate with non-adherence by pill count being most frequent in the first six months of ART 
treatment in our cohort.  
Sensitivity was high but specificity was low for the use of pill count adherence as a proxy for viral 
load outcomes. While some studies have demonstrated an association between pharmacy adherence 
measures and virologic outcomes others have found poor agreement between the two measures. For 
instance, a Mozambican study reported pill count to be a reliable indicator of undetectable viral load 
using an adherence threshold of >95% (78). The combination of pill count and self-reported 
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adherence was also found to be highly associated with virologic failure in a South African case-
control study (110). Similarly, Muyingo et al. (71) reported a significant relationship between 100% 
DPR and viral suppression in the first year of ART. On the other hand, pharmacy refill adherence 
measures were poorly predictive of virological failure in a Johannesburg urban clinic cohort, although 
pill count was reliable in identifying non-adherent patients (237). Goldman et al. (238) investigated 
the ability of self-report and MPR to predict viral suppression and both adherence measures were 
found to be poorly correlated with viral load outcomes.  
The use of different adherence measures, varying optimal adherence thresholds, timing of viral load 
measurements, definition of viral load suppression and time on ART all influence the relationship 
between adherence and virologic outcomes (77, 111, 239). Although we used an adherence threshold 
of ≥95%, viral suppression has been reported to be attained in patients with 85-94% on long term 
ART (72). Furthermore, while pill counts can provide a more objective method of adherence 
assessment, patient manipulation is possible as non-adherent patients may discard or leave behind 
medication not taken and return the desired number of pills to demonstrate good adherence (37, 73).  
Although plasma viral suppression is possible with sub-optimal adherence, low-level viral replication 
continues in the plasma and reservoirs such as the central nervous system and genital tract, the long 
term effects of which have not been fully elucidated (84, 85). Therefore, high adherence to ART 
remains key to ensuring the best clinical outcomes.     
Objective 2: Determine if baseline socio-demographic variables predict long term adherence 
behaviour 
Baseline patient demographics and socio-economic variables were not predictive of adherence in this 
cohort (see Appendix O – additional data presented). Lower adherence was observed in females and 
patients younger than 40 years and adherence was better in patients who were the primary 
breadwinner, head of a household or employed. However, none of these associations were statistically 
significant.  
Cross-sectional and short term cohort-based adherence studies have reported certain patient 
characteristics and socio-economic variables can influence adherence. For instance, higher rates of 
non-adherence were observed in men who were single (49%), unemployed (56%) or had a tertiary 
education (60%) in a rural patient cohort (116). Van Dyk et al. (124) demonstrated lower adherence 
was significantly associated with younger age and non-disclosure of HIV status and ART use, 
whereas Maqutu et al. (240) found ≥95% adherence was better in younger males and older females 
and lower in older patients with no schooling. In a Kwa-Zulu Natal cohort, patients in urban areas 
were three times more likely to be adherent compared to those in rural areas and patients with no 
partner were 80% more likely to report ≥95% adherence, whereas poor socioeconomic conditions 
were associated with lower adherence (aOR1.56; 95% CI 1.28-1.89) (51). In contrast, a long term 
67 
 
adherence study in South Africa found no relation between patient demographic characteristics and 
adherence which is consistent with the findings in our study (27).  
In resource limited countries, poor socio-economic conditions, unemployment, financial constraints, 
low level of education and inadequate access to health care and treatment can impair adherence (135, 
165, 167, 169). These factors may not have impacted adherence in our cohort as the clinic location 
was easily accessible through public transport and patients were reimbursed for transportation costs. 
In addition, patients received pre-ART education and post-ART adherence support and counselling in 
their local language, isiZulu, by trained counsellors and this may have facilitated adherence in patients 
with limited education or poor English literacy levels as there was no language barrier between 
patients and clinic staff.   
Objective 3: Determine the effect of ARV regimen change on adherence by assessing pill count and 
viral load data six months before and after switch to a second line treatment regimen  
High pill burden, regimen complexity and dosing more than once a day have been reported to impair 
adherence (172). This is evidenced by lower adherence often observed with PI-based regimens (28, 
42, 123, 216). Patients who experienced treatment failure in our cohort were switched to a second line 
boosted PI-based regimen consisting of LPV/r plus two NNRTIs. The number of pills in this regimen 
was almost double compared to the first line regimens. In addition, the dosing frequency changed 
from once daily to twice daily. The additional pill burden and increase in dosing frequency did not 
impair adherence and viral load suppression improved significantly in our treatment failure patients. 
Our findings support similar improved results observed by Murphy et al. (241) on second line 
treatment outcomes in South Africa. The use of a boosted PI regimen, provision of enhanced 
adherence counselling to patients on the implications of treatment failure with reinforcement of the 
importance of good adherence before and after the regimen change and enlisting a treatment 
supporter, where possible, may account for the improved outcomes (242-245). 
 
Objective 4: Assess ART adherence during episode/s of recurrent TB infection by pill count and 
viral load data 
HIV infected individuals have a 20 to 30 times greater risk for developing active TB disease and this 
has fuelled the TB epidemic in South Africa where HIV and TB co-infection rates are the highest 
globally (186). Concurrent treatment of both diseases has been shown to significantly reduce 
morbidity and mortality (222, 246, 247). However, patients have to cope with the additional pill 
burden and overlapping side effects when taking ART and anti-TB drugs concomitantly and this may 
lead to impaired or selective adherence to either ART or TB medication (187, 248). We found no 
significant changes in ART adherence or viral suppression in patients on concomitant ART and 
recurrent TB treatment. A study within several different HIV-TB co-infected patient cohorts in South 
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Africa  also found that patients were able to maintain good adherence to both treatments 
simultaneously (249). 
 
Objective 5: Determine if there are differences in adherence between patients receiving a monthly 
supply versus three monthly ART supply by pill count 
Patients who were virally suppressed, stable on ART and demonstrated good adherence by pill count 
were sometimes provided with a three month ART supply in the TRuTH study. Two hundred and 
sixty-seven patients received a three month ART supply at least once and mean adherence for all three 
month ART packages dispensed was >99% with optimal adherence attained by 97.5% of patients. A 
subset of patients (n=46) received a three monthly ART supply at three or more study visits and all 
patients in this group had optimal adherence levels.  
In an overburdened public health care setting, providing patients with a two or three month ART 
supply can ease clinic patient load and reduce the need for monthly clinic visits which impact 
negatively on patient finances and employment. In line with the need to improve service delivery and 
alleviate pressure on the over-extended public health sector facilities, South Africa recently 
introduced the Centralised Chronic Medicine Dispensing and Distribution (CCMDD) programme 
where stable, virologically suppressed patients on ART for at least 12 months are able to collect their 
ART medication every two or three months at a private pharmacy, general practitioner, adherence 
club or community pick up point closest to them (250, 251). Our results provide reassurance that 
stable patients can maintain optimal adherence when provided with more than a month of ART supply 
at a time. 
 
4.2 Study Limitations 
This is a retrospective study of ART adherence in the SAPiT and TRuTH studies, both of which were 
conducted at a single research site. Adherence behaviour may have been influenced by participation in 
a clinical trial, where patients were routinely monitored, counselled, telephonically or physically 
tracked and reimbursed for study visits. Therefore, adherence in this population may not be 
generalizable to other population settings.  
Investigation of factors associated with adherence behaviour are limited to available baseline patient, 
socio-economic and treatment data and changes in baseline characteristics over time were not 
captured to reliably inform their association with adherence post enrolment into the trials. 
Furthermore, not all eligible patients who completed follow up from the SAPiT study were enrolled 
into the TRuTH study as some were lost to follow up, demised or declined participation. 
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Assessment of adherence by pill count can be prone to bias. Non-adherent patients familiar with the 
pill count assessment may ‘count tablets’ and return the required number of pills to demonstrate good 
adherence. In addition, pill count could not be completed if patients did not bring their remaining 
tablets at a visit and an accurate adherence calculation would not be possible for patients who reported 
lost pills and/or pills left at home.  
4.3 Recommendations for clinical practice 
 Pill count was not a good predictor of virologic failure and we recommend viral load 
measurement as the benchmark for monitoring treatment response. However, adherence during 
the six months post-ART initiation period has been shown to impact long term treatment 
outcomes and viral load is not measured within this crucial time, only six months after initiating 
ART and thereafter annually per in-country treatment guidelines. The incidence of treatment 
failures was highest in the initial two years after ART initiation in our cohort. Therefore, pill 
count is valuable as a quick, simple measure of adherence to identify patients with early 
adherence challenges and allow for timeous intervention.  
 Pharmacists are ideally placed to identify patients experiencing adherence challenges using 
pharmacy adherence measures such as pill count or drug refill dates and can therefore play a key 
role in either providing or referring patients for appropriate adherence support and counselling.  
 Where possible, the provision of adherence support measures such as individual and group ART 
counselling sessions, provision of pill boxes, the use of treatment supporters and telephonic 
tracking of patients who miss a clinic appointment date can assist patient adherence. 
 Providing an extended ART supply to virally suppressed, stable patients with optimal adherence 
to ART for longer than a year is an effective strategy to reduce patient visits and clinic workload 
in our resource strained public health sector. 
 The increased pill burden associated with concurrent treatment of drug sensitive TB and ART 
does not impair adherence to ART. However, adherence support interventions may be required in 
patients who already have suboptimal adherence prior starting TB treatment. 
4.4 Recommendations for future research 
Various patient adherence support measures were used in the SAPiT and TRuTH studies and further 
investigation is required to determine which of these are time and cost effective for adoption into our 
resource limited public health care setting. We demonstrated that providing stable patients with a 
three month ART supply was feasible as optimal adherence was still maintained over this extended 
time between clinic visits. This has the potential to reduce clinic patient load and alleviate time and 
economic burden on patients in a busy public health care setting and is currently being investigated 
further in a randomized control trial (252). In addition, outcomes from the CCMDD programme need 
70 
 
to be monitored and reported to determine if patients are remaining in care and are adherent to 
treatment.  
With the expansion of ART access to all PLWH, it is essential to monitor the impact of rapid 
treatment scale up on long term adherence. Providing adherence support and retaining patients in care 
is advocated in local treatment guidelines, however, recent data show that only 74% of patients 
initiated on ART in 2015-2016 remained in care after 12 months (221). Therefore, further research is 
needed to determine how long term optimal adherence to ART may be successfully maintained with 
the increasing numbers of PLWH entering care.  
Point-of-care viral load measurements can reduce costs and thereby improve access to viral load 
monitoring in our resource limited health care setting. Ongoing research in this promising field is 
important to determine if the diagnostic accuracy of point of care viral load results are comparable to 
current laboratory based viral load monitoring.  
4.5 Conclusion 
In summary, our study found that optimal long-term adherence with good treatment outcomes are 
possible within a structured ART programme with close adherence monitoring and support. While pill 
count was not a reliable standalone predictor of virologic failure in this study, adherence patterns 
during the initial six months after ART initiation has been shown to impact long term treatment 
outcomes, therefore, pill count may be used as a quick, simple measure of adherence to identify 
patients with early adherence challenges and provide the opportunity for timeous adherence 
interventions. Viral load measurement remains the benchmark for monitoring treatment response as 
advocated by current guidelines. 
With South Africa’s adoption of the UTT strategy and rapid scale up of ART provision, it is 
imperative that patient adherence is continually monitored and supported to ensure a successful ART 
programme in South Africa.  
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Appendix O – Supplementary Data 
Association of demographics, socio-economic conditions and clinical characteristics to ART 
adherence  
Variable <95% (n=14) 
≥95% 
(n=256) p-value 
Gender    
Female 9  139  0.465 
Male 5  117   
Age    
20-25 3  28 0.221 
25-40 10  166   
≥40 1  62   
Head of household    
Partner 1  10  0.465 
Self 8  171  
Parent 5  57  
Other 0 18   
Primary breadwinnera    
Self 7  183  0.149 
Partner 2  11   
Parent 4  48   
Other 0 14   
Current marital status    
No partner 14  210  0.082 
Stable partner 0 46   
Occupation of patient    
Student 0 6  0.090 
Employed 5  159   
Unemployed 9  91  
Educationa    
Primary school or less  3 55 0.934 
Secondary school not 
complete  
7 116  
Secondary school complete 4 84  
    
Telephonea    
Yes 1  55  0.196 
No 13  200  
Access to both tap water and 
electricitya 
   
Yes 12  224  0.813 
No 2 31  
Number of adults and childrenb    
110 
 
Variable <95% (n=14) 
≥95% 
(n=256) p-value 
<5 9 189 0.572 
6-10 4 53  
>10 0 10  
Tested for HIV prior studyc    
Yes 10 (71.4) 124 (50.2) 0.122 
No 4 (28.6) 123 (49.8)  
Disclosed HIV statusc    
Yes 10 (71.4) 144 (58.3) 0.331 
No 4 (28.6) 103 (41.7)  
CD4+ count (cells/mm3)d    
≤50 2 48 0.952 
51-200 7 119  
201-350 3 61  
>350 2 28  
Viral load (copies/mL)d    
≤5000 0 20 0.182 
5001-30000 4 35  
30001-100000 4 52  
>100000 5 146  
WHO staging    
stage3 13  241 0.843 
stage4 1  15  
a 1 missing data 
b 5 missing data 
c  9 missing data 
d  4 missing data 
ART – antiretroviral therapy 
WHO – World Health Organization 
 
